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ABSTRACT 
Amyotrophic lateral sclerosis (ALS) is a devastating, adult onset motor neuron disease 
(MND) that has no effective treatment to date. The current study investigates the possibility 
of targeting protein aggregation pathway for treatment. Modulation of this pathway is 
approached through targeting Arfaptin2 protein. The C-terminal of Arfaptin2 (HC-ARFIP2), 
a dominant negative form of Arfaptin2, has been shown to have a neuroprotective property 
that maintains the proteasome activity and induces degradation of misfolded proteins.  
We thus proposed that the HC-ARFIP2 improves neuronal survival in ALS via 
maintaining the proteasomal pathway, which in turn will decrease neuron toxicity and improve 
neuronal survival. Expression of HC-ARFIP2 in primary motor neuron cultures using LV-
based vector, improved motor neuron survival significantly. The prosurvival effect was 
observable even in cells treated with H2O2 in both SOD1G93A transgenic and non-transgenic 
cells. A further investigation on the pathway of which HC-ARFIP2 exerts it neuroprotective 
effect showed that HC-ARFIP2 induces Akt phosphorylation by decreasing its dominant 
negative modulator, PTEN. In addition, protein degradation pathway-markers (p62, LC3II, 
ULK1) showed significant changes in response to HC-ARFIP2 expression. Furthermore, 
Arfaptin2 showed colocalisation with SOD1 and overexpression of FL-ARFIP2 caused 
aggregates formation in HEK293T cells compared to HC-ARFIP2 expression that maintained 
the cytoplasmic distribution of SOD1. 
A scAAV9-based vector was produced to replicate these observations in vivo. The desired 
viral titre could not be obtained within the time course of the PhD. 
In conclusion, the study presented here has provided a proof of concept that Arfaptin2 is 
involved in protein aggregation in ALS. In addition, HC-ARFIP2 expression can improve 
motor neuron survival in vitro through activation of Akt and proteasome activity. 
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1.1 Amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS) is an adult onset motor neuron disease 
(MND), in which mainly upper motor neurons (UMN) in motor cortex and lower 
motor neurons (LMN) of brainstem and spinal cord degenerate. Nevertheless, it is now 
considered a multisystem disease as other types of neurons in addition to motor 
neurons can be affected. The average age of onset is 50-60 years; however, juvenile 
onset has been reported. The incidence is approximately 4/100,000 worldwide in 
which men are more commonly affected than women. It is a progressive and 
devastating disease in which the average survival is three years from the onset of 
symptoms, and death usually occurs due to respiratory failure (Shaw, 2005, Ferraiuolo 
et al., 2011).  
MND can be subdivided into four subclasses according to the affected motor 
neurons; ALS, in which both UMNs and LMNs are affected; primary lateral sclerosis 
(PLS), in which only the UMNs are affected; progressive muscular atrophy (PMA), in 
which only LMNs are affected; and progressive bulbar palsy (PBP), in which only the 
bulbar musculature is affected. However, most of these subclasses progress into ALS. 
ALS has been reported to be accompanied with frontotemporal lobar degeneration 
(ALS/FTLD) in 20% of cases (Shaw, 2005). Definitive diagnosis of ALS is 
complicated and follows specific criteria. According to El Escorial criteria, ALS 
diagnosis can be divided into: definite, in which both UMN and LMN in three or more 
regions are affected; probable, in which UMN and LMN are affected in less than three 
regions; possible, in which either UMN or LMN are affected; and laboratory-
supported probable, in which UMN and LMN are affected and supported by laboratory 
tests (Bradley et al., 2003). 
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Symptoms develop due to muscle weakness and muscle wasting; most commonly 
starts in the upper limbs. Depending on which muscles are affected, ALS patients may 
show symptoms like fasciculation, muscle cramps, dysphagia and bulbar impairment 
(Bradley et al., 2003).  
1.1.1 Types 
ALS is divided into two types according to the genetic cause:  
1.1.1.1 Familial ALS (FALS) 
FALS accounts for approximately 10% of ALS cases. It mostly shows autosomal 
dominant inheritance, however, autosomal recessive and X-linked inheritance have 
been reported (Hentati et al., 1994, Maruyama et al., 2010, Orlacchio et al., 2010, 
Deng et al., 2011b). Over 10 genes have been identified to be involved in the FALS 
and some of them have unknown functions. The most studied mutated gene in FALS 
is the copper-zinc superoxide dismutase-1 gene (SOD1), which was first identified by 
Rosen and colleagues, present in 20% of FALS cases (Rosen et al., 1994, Ferraiuolo 
et al., 2011). However, the most common mutation found in FALS is a hexanucleotide 
GGGGCC repeat expansions at chromosome 9 open reading frame 72 (C9ORF72) 
(DeJesus-Hernandez et al., 2011, Renton et al., 2011) 
1.1.1.2 Sporadic ALS (SALS) 
SALS accounts for the remaining 90% of ALS cases. The exact causes of SALS 
are still unknown but there is a hypothesis that an acquired nucleic acid change triggers 
the initiation of ALS that is age- and environmental-dependent. Such factors are 
smoking (Kamel et al., 1999), ingestion of foods containing neurotoxins such as Cycad 
flour (Esclaire et al., 1999, Armon, 2005), and increased cardiovascular fitness (Turner 
et al., 2011). 
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1.1.2 Pathogenesis  
ALS seems to be a multi-factorial disease and the exact pathogenesis of the disease 
is still debated. However, several factors have been identified to be involved in the 
pathogenesis of ALS (Figure 1.1), which are:  
 
 
Pathogenesis of ALS
Impaired endosomal 
trafficking and axonal 
transport
Excitotoxicity
Mitochondrial 
dysfunction
Oxidative stress
Genetic mutations
Glial dysfunction
Endoplasmic reticulum 
stress
Dysregulated RNA 
transcription and 
processing
Protein aggregates
 
 
 
 
 
Figure 1.1: Pathogenic pathways involved in ALS.  
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1.1.2.1 Genetic mutations  
Genetic mutations were reported in some ALS cases. Genes reported to be mutated 
in ALS cases are listed in Table 1.1. Some mutations might be involved in ALS 
pathogenesis through a toxic gain of function mechanism rather than loss of function, 
a hypothesis was raised after noticing that SOD1 knockout mice did not develop MND 
phenotype (Reaume et al., 1996, Cho et al., 2011), while expressing mutant human 
SOD1 (hSOD1) did show MND symptoms (Gurney et al., 1994). Mutant SOD1 is the 
most studied gene defect in ALS. Over 140 mutations in SOD1 gene have been 
identified (Chattopadhyay & Valentine 2009, Polymenidou & Cleveland 2011) 
Some mutations might affect protein folding and involve the protein degradation 
pathway. For instance, mutated valosin-containing protein (VCP) causes disruption to 
the ubiquitin proteasome system (UPS) which causes accumulation of protein 
aggregates in motor neurons (Johnson et al., 2010b). In support of this hypothesis, 
many ALS-related mutated genes are involved in protein degradation pathways. Such 
genes are CHMP2B, UBQLN2, P62, OPTN and VCP (Chalasani et al., 2014). 
However, a study on Dutch cohorts showed that VCP mutations in ALS are very rare 
and that the identified mutations were shown to be benign according to protein 
prediction software (Koppers et al., 2011). 
Other mutations cause a disease by loss of function mechanism. An example is 
ALS2 mutations that cause the production of unstable proteins. These products degrade 
frequently and the protein level were found to be significantly decreased in 
lymphoblasts of ALS patients (Yamanaka et al., 2003). 
The hexanucleotide repeat expansion in C9ORF72 is the most common mutation 
related to ALS, and it is detected in many FALS and SALS cases (DeJesus-Hernandez 
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et al., 2011, Renton et al., 2011). It has been reported that these hexanucleotide repeats 
are expanded in about 50% of FALS and 21% of SALS (Renton et al., 2011). Although 
the actual function of C9ORF72 is still unknown, it is highly conserved between 
species. The normal repeat size range between 0-22, while disease associated repeats 
are over 1000. C9ORF72 was found to produce three transcripts that encodes for two 
protein isoforms. Transcript 1 and 3 encode for isoform a, while transcript 2 encodes 
for isoform b. The hexanucleotide repeat expansions seem to cause variant 1 
transcription interruption which leads to reduced production of isoform a (DeJesus-
Hernandez et al., 2011). Therefore, it was suggested that these repeat expansions are 
involved in the pathogenesis by disrupting gene expression or splicing or by the 
formation of toxic RNA that disrupt some cellular physiological pathways (DeJesus-
Hernandez et al., 2011, Renton et al., 2011).  
In general, the exact effect of ALS-related mutations on motor neurodegeneration 
is still vague. 
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Table 1.1: List of genes related to ALS. 
Gene  Gene locus Function/ 
pathogenic pathway  
References  
SOD1 21q22.11 Superoxide 
metabolism 
(Rosen et al., 
1993) 
FUS 16q11.2 RNA processing (Kwiatkowski et 
al., 2009) 
TARDBP 1p36.22 
 
RNA processing (Sreedharan et 
al., 2008) 
C9ORF72 9p21.2 Unknown, RNA 
processing, 
endosomal trafficking 
(DeJesus-
Hernandez et al., 
2011, Renton et 
al., 2011, Farg et 
al., 2014) 
OPTN 10p13 
 
Vesicular trafficking, 
autophagy 
(Maruyama et 
al., 2010) 
VCP 9p13.3 Vesicular trafficking, 
autophagy 
(Johnson et al., 
2010a) 
UBQLN2 Xp11.21 Protein degradation (Deng et al., 
2011b) 
SQSTM1/p62 5q35 
 
Protein degradaiton (Fecto et al., 
2011) 
profilin 1 (PFN1) 17p13.3 
 
Cytoskeleton 
arrangement  
(Wu et al., 2012) 
Chapter 1: Introduction 
8 
 
 
ALS2 2q33.1  
 
Vesicle trafficking, 
guanine-nucleotide 
exchange factor 
(GEF). 
(Yang et al., 
2001) 
Senataxin (SETX) 9q34.13 DNA repair (Chen et al., 
2004) 
Vesicle-associated 
membrane protein/ 
synaptobrevin-
associated membrane 
protein B (VAPB) 
20q13.33 Vesicle trafficking (Nishimura et 
al., 2004) 
Dynactin1 (DCTN1) 2p13 
 
Vesicle trafficking (Munch et al., 
2004) 
Angiogenin (ANG) 14q11.1-
q11.2  
 
RNA processing (Greenway et al., 
2006) 
charged 
multivesicular body 
protein 2B (CHMP2B) 
3p11.2 Vesicle trafficking (Parkinson et al., 
2006) 
Polyphosphoinositide 
phosphatase (FIG4) 
6q21 Vesicle trafficking (Chow et al., 
2009) 
D-amino-acid oxidase 
(DAO) 
12q24 
 
Excitotoxicity (Mitchell et al., 
2010) 
Ataxin 2 (ATXN2) 12q24.1 
 
RNA processing (Elden et al., 
2010) 
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Matrin 3 (MATR3) 5q31.2 
 
RNA processing (Johnson et al., 
2014) 
Sigma receptor 1 
(SIGMAR1) 
9p13.3 Calcium homeostasis  (Luty et al., 
2010, Al-Saif et 
al., 2011) 
Spatacsin/spastic 
paraplegia 11 
(SPG11) 
15q14 Unknown  (Orlacchio et al., 
2010) 
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1.1.2.2 Oxidative stress  
 Oxidative stress is a mechanism in which cell damage is induced by excessive 
reactive oxygen species (ROS). ROS are produced normally as part of cellular 
metabolism and they maintain cellular homeostasis. However, increased production 
of ROS may cause damage to several cellular components such as proteins, lipids and 
DNA. Thus, increased ROS production might play a critical role in ALS pathogenesis. 
These highly reactive radicals are inactivated by antioxidants (Ramalingam and Kim, 
2012). An antioxidant that is known to be involved in ALS pathogenesis is SOD1. 
Although SOD1 might not be critical for the development of the nervous system, it is 
necessary for neuronal survival under oxidative stress, and its absence makes the cells 
prone to cell death by oxidative stress (Reaume et al., 1996). 
1.1.2.3 Mitochondrial dysfunction  
Mitochondrial dysfunction is frequently associated with aging and age-related 
diseases. It was suggested to be involved in ALS pathogenesis through mutation or 
deletion of mitochondrial DNA (mtDNA) that interrupts its functions (Miquel, 1992, 
Wiedemann et al., 2002). These include disrupted electron transport chain, 
mitochondrial calcium buffering, and abnormal mitochondrial morphology. This 
mtDNA damage can be caused by oxidative stress which also damages the 
mitochondrial proteins and membrane lipids (Karbowski and Neutzner, 2011). In 
accordance with that hypothesis, mitochondria transfected with SALS patients’ 
mtDNA showed similar defects to those observed in SALS patients and mouse models 
(Swerdlow et al., 1998). Mitochondrial dysfunction can be also caused by 
accumulation of protein aggregates in mitochondria that cause disruption of 
mitochondrial fusion (Wang et al., 2009).  
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1.1.2.4 Excitotoxicity  
Excitotoxicity causes neurodegeneration by excessive glutamatergic 
neurotransmission. Glutamate is the major excitatory neurotransmitter, which is 
released from presynaptic neurons and activates ionotropic glutamate receptors on the 
postsynaptic neurons. Postsynaptic receptors are the α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptor, N-methyl D-aspartate (NMDA) receptor 
and the kainate (KA) receptor; which then induce an influx of calcium and sodium 
ions. The ion influx causes depolarization of the neuron and production of action 
potential. Excitotoxicity is induced by increased glutamate release from the 
presynaptic neuron (Alexander et al., 2000), decreased glutamate up-take by 
excitatory amino acid transporters (EAAT) (Maragakis et al., 2004) or increased 
sensitivity of post synaptic neurons which is caused by either a defect in glutamate 
receptors (Kuner et al., 2005), or by increased cell vulnerability due to mitochondrial 
damage (Novelli et al., 1988, Van Den Bosch et al., 2006).  Further evidence of the 
involvement of glutamate excitotoxicity in the pathogenesis of ALS is that Riluzole, 
which acts as a glutamate neurotransmission inhibitor, is the only partially-effective 
therapy for ALS (Cheah et al., 2010). However, its effect is modest, which indicates 
the involvement of other pathways in the pathogenesis.  
1.1.2.5 Impaired endosomal trafficking and axonal transport  
Endosomal trafficking and axonal transport might play a role in ALS pathogenesis 
as the distinct structure of neurons make them require proper intracellular trafficking 
for protein and organelle transport between the dendrites, cell body and axon, and the 
turnover of membrane proteins (Ferraiuolo et al., 2011). In accordance with that 
hypothesis, mutations to ALS2 gene, which encodes for alsin, has been found in 
juvenile ALS cases. Alsin is involved in nuclear import and export, vesicle transport 
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and endosomal trafficking. ALS-related mutations in ALS2 showed a loss of function 
mechanism (Yang et al., 2001). Furthermore, alsin affects the AMPA glutamate 
receptor subunit 2 (GluR2), a calcium-impermeable subunit as its loss of function was 
found to affect the localisation of glutamate receptor interacting protein1 (GRIP1), 
which regulates the presentation of GluR2 on the synaptic surface. This disturbance 
of GRIP1 localisation causes decreased presentation of GluR2 on cell surface, which 
in turn increases  calcium permeability and leads to excitotoxicity (Lai et al., 2006). 
In addition, pre-symptomatic transgenic mouse models expressing mutated human 
SOD1  at position 93 from glycine to alanine (SOD1G93A), showed impaired axonal 
transport signs, which indicates the involvement of this pathway in the pathogenesis 
of ALS (Williamson and Cleveland, 1999, Bilsland et al., 2010) 
1.1.2.6 Glial dysfunction  
Glial cells are a collective name for cell types present in the central nervous system 
(CNS) other than neurons. It includes astocytes, oligodendrocytes and microglia. They 
are involved in myelination, immune response, nutrition transport and homeostatic 
maintainance of the CNS. Glial dysfunction has been implicated in ALS in two ways. 
Firstly, neuroinflammation is a mechanism in which neurodegeneration is induced by 
inflammatory mediators that are secreted from glial cells. Increased levels of cytokines 
were detected in serum and cerebro-spinal fluid of ALS patients (Kuhle et al., 2009) 
and secreted from a SOD1 microglia model challenged by lipopolysaccharide (LPS) 
(Sargsyan et al., 2009). The involvement of immune system in pathogenesis of ALS 
is further supported by the detection of increased messenger RNA (mRNA) levels of 
complement system components, which are involved in the innate immune response, 
in spinal cord of ALS patients. In addition, increased dendritic cells and cytotoxic T-
cells were found in ALS patients (Sta et al., 2011).  
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Secondly, glial cell pathology has been reported as a cause of neurodegeneration 
(Maragakis et al., 2004, Diaz-Amarilla et al., 2011). Astrocytes extracted from 
symptomatic SOD1G93A rat model exhibited significant differences compared with 
astrocytes from non-transgenic littermates and neonatal SOD1G93A. Astrocytes from 
symptomatic SOD1G93A were lacking the expression of EAAT2 receptor and low 
Glial fibrillary acidic protein (GFAP) marker. Additionally, they have an increased 
proliferation capability and have been found to localize with degenerating motor 
neurons in spinal cord of SOD1G93A mice (Diaz-Amarilla et al., 2011). Furthermore, 
abnormal microglial morphology and overactivation was observed in vivo in 
SOD1G93A mice that might increase their sensitivity to CNS insults (Sargsyan et al., 
2009, Dibaj et al., 2011). 
Emerging evidence showed that co-culture of astrocytes from ALS animal models 
or from FALS and SALS patients with healthy motor neurons led to increased motor 
neurodegeneration compared to healthy co-cultures (Diaz-Amarilla et al., 2011, 
Haidet-Phillips et al., 2011, Re et al., 2014). This neurotoxic effect was found to be 
Bax-dependent, which is a pro-apoptotic molecule from the Bcl-2 family, and caspase-
independent, which is involved in apoptosis (Re et al., 2014). These studies indicate 
that glial cells are involved in the pathogenesis of ALS and could correlate with the 
progression of the disease. 
1.1.2.7 Endoplasmic reticulum (ER) stress  
ER stress is caused by inbalanced calcium homeostasis, oxidative stress, increased 
secretory protein synthesis, protein misfolding, sugar/glucose deficiency or altered 
glycosylation. In order to survive ER stress, ER undergoes what is called unfolded 
protein response (UPR) (Swarup et al., 2011). The aim of UPR is to refold unfolded 
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or misfolded proteins. If this aim could not be achieved, UPR induces protein 
degradation, in which misfolded proteins are recognised by protein chaperones, such 
as protein disulphide isomerase (PDI) and immunoglobulin binding protein (BiP). 
These molecules residing in the ER help in correcting and avert aggregation of 
misfolded proteins around the ER (Kaufman, 2002). Both PDI and BiP have been 
found to colocalise with SOD1-positive inclusions. Increased UPR activity has been 
found in pre-symptomatic and symptomatic SOD1G93A which indicates the 
involvement of ER stress in the pathogenesis of ALS (Walker and Atkin, 2011).  
1.1.2.8 Dysregulated RNA transcription and processing  
Dysregulated RNA processing has been proposed to be involved in ALS 
pathogenesis as mutations in two genes encoding RNA-binding proteins have been 
identified in some SALS and FALS cases. Transactive response DNA-binding protein 
43 (TDP43) and Fused in sarcoma (FUS) protein are ALS-linked proteins and they are 
involved in RNA processing, transcription, splicing and mRNA transport. The exact 
mechanism of involvement of these proteins in ALS pathogenesis is undetermined. 
However, several mechanisms have been suggested which include disruption of 
axonal mRNA transport, RNA metabolism and nuclear mRNA export (reviewed by 
(Ferraiuolo et al., 2011). 
1.1.2.9 Protein aggregation 
Protein aggregates are a hallmark of many, if not all, neurodegenerative diseases. 
These intracytoplasmic aggregates in ALS mostly localise in the motor neuron but are 
often detected in glial cells (Chattopadhyay and Valentine, 2009).  
 Protein inclusions, are non-membranous, stable, detergent-insoluble, and contain 
poly-ubiquitinated proteins with high molecular weights, which are formed due to 
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either overexpression of a protein which exceeds the degradation capacity or defective 
proteolytic pathways (Johnston et al., 1998). 
Some diseases feature distinct inclusion structures that might distinguish them 
from other neurodegenerative diseases. Three inclusion structures have been reported 
in the motor neurons of ALS patients which are skein-like inclusions, Bunina bodies 
and hyaline bodies, in which the first structure is the most common and specific to 
ALS (Wood et al., 2003). ALS distinct skein-like inclusions are Sequestosome 1 
(p62)-, and ubiquitin-positive and consist of other different proteins (Deng et al., 
2011a). These proteins may vary according to the cause of the disease. It has been 
found that protein inclusions start as small dot-like or filament-like aggregates that 
gain size by fusing with other aggregates (Li et al., 2011). 
There are three common hypotheses regarding the role of protein aggregates in 
neurodegenerative diseases. Firstly, protein aggregates have toxic effect on neurons 
and induce their death. Secondly, the aggregates are formed because of other toxic 
effects. Finally, aggregates are formed as a defensive response to protect the cells 
against toxic abnormal proteins (Baloh, 2011). The first two hypothesis are somehow 
connected and mounting evidences support those hypotheses. More details are 
discussed below. 
1.1.2.9.1 Proteins involved 
SOD1 is a 153 amino acid (a.a) protein that is normally expressed as a dimer in 
the cytoplasm of neurons. SOD1 is an antioxidant that converts superoxide into 
hydrogen peroxide and oxygen. Mutant SOD1 is the most studied gene defect in ALS. 
SOD1-positive aggregates are observed in SOD1-related ALS cases (Chattopadhyay 
and Valentine, 2009, Polymenidou and Cleveland, 2011). Misfolded SOD1 is not 
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specific to SOD1-FALS cases, as over-oxidised and aggregated wild type (WT) SOD1 
has been reported in a subset of SALS cases (Guareschi et al., 2012). 
TDP43 is a DNA-binding protein that is involved in maintenance of several RNA 
metabolism processes in the nucleus and cytoplasm (Baloh, 2011). It is a 414 a.a 
protein with a molecular weight of 43 kDa; however, a 37 and 25 kDa fragment have 
been reported in normal cells. It is predominantly expressed as a soluble monomeric 
or dimeric protein localised in the nucleus (Ayala et al., 2011). However, it has been 
found to redistribute to the cytoplasm in ALS and TDP43-positive-FTLD cases, which 
might induce its aggregation (van Eersel et al., 2011). It is a component of protein 
aggregates in 90% of ALS (Neumann et al., 2006). 
The FUS protein, also known as translocation in liposarcoma (TLS), is a 526 a.a 
RNA-binding protein expressed predominantly in the nucleus and is involved in some 
RNA processing pathways. Mutations in the FUS gene have been detected in FALS 
cases (Kwiatkowski et al., 2009, Vance et al., 2009). However, FUS-immunoreactive 
inclusions were detected in all SALS, ALS/FTLD, SOD1-negative FALS cases and 
even in atypical FTLD cases that are TDP43-negative, but were absent from the 
SOD1-FALS cases (Deng et al., 2010). 
Ubiquitin and p62 are proteins involved in the UPS, which is one of the 
proteolytic machineries. Ubiquitin is a 76 a.a protein that tags other proteins for 
different cellular physiological pathways. It binds to the ubiquitin-activating enzyme 
(E1) that transfers the ubiquitin to an ubiquitin-conjugating enzyme (E2), which either 
transfers the ubiquitin to an ubiquitin-ligase (E3) or forms a complex with ubiquitin 
and E3. Those complexes tag the target proteins with one or more ubiquitin molecules, 
a process called ubiquitination. The poly-ubiquitinated protein is then recognised by 
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26S proteasome complex, which degrades the misfolded protein. p62 is an ubiquitin-
binding protein that is encoded by SQSTM1 gene and is involved in both the UPS and 
autophagy degradation pathways (Figure 1.2) (Nijholt et al., 2011, Jansen et al., 2014).  
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Figure 1.2: Schematic explanation of the two major protein degradation 
pathways. Misfolded proteins are degraded by ubiquitin-proteasome system, in 
which the protein is being tagged with ubiquitin Ub, facilitated by the ubiquitin-
activating enzyme E1, ubiquitin-conjugating enzyme E2, and the ubiquitin-ligase 
E3. The ubiquitinated protein is then degraded by the 26S proteasome, or being 
degraded by autophagy, in which ubiquitinated protein aggregate is further tagged 
with p62 and engulfed in autophagosome, which is digested by the lysosome. 
Adapted from (Millhauser, 2007, Clague and Urbe, 2010) 
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Ubiquilin2 (UBQLN2) immunoreactive inclusions have been found in 
hippocampus and spinal cord of different ALS cases, including cases without 
UBQLN2, SOD1, TDP43 or FUS mutations (Deng et al., 2011b). UBQLN2 is a 
member of the ubiquitin-like protein family, which are responsible for ubiquitinated 
protein degradation via the UPS. It is normally localised in the cytoplasm of different 
types of cells including neurons. However, it has been shown that under hypoxic 
conditions cells undergo DNA fragmentation that can be prevented by overexpression 
of UBQLN2. This might indicate that UBQLN2 play a crucial role in cell survival (Ko 
et al., 2002). 
Optineurin (OPTN) immunoreactive inclusions found in motor neurons of SALS 
and SOD1-FALS subjects were also TDP43 and ubiquitin-positive (Maruyama et al., 
2010, Ito et al., 2011). However, this has been contested by two other groups (Deng et 
al., 2011a, Hortobagyi et al., 2011), in which the former found that OPTN-
immunoreactive inclusions present in all SALS, SOD1-negative and OPTN-negative 
FALS cases but not SOD1-FALS cases. While the later found that the majority of 
TDP43-positive aggregates in ALS patients samples were OPTN-negative and none 
of the FUS-positive or SOD1-positive FALS patient samples was associated with 
OPTN. OPTN is involved in endocytosis, signal transduction, vesicular trafficking and 
autophagy (Zhu et al., 2007, Nagabhushana et al., 2010, Chalasani et al., 2014). 
VCP is a cytosolic protein that is involved in many cellular processes such as 
membrane fusion, cell proliferation, nuclear trafficking, protein degradation and 
endoplasmic reticulum-associated degradation (ERAD). VCP-immunoreactive 
aggregates were detected in ALS and Parkinson’s disease (PD) affected neurons 
(Ishigaki et al., 2004). 
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Finally, c9RAN is the collective name for C9orf72 repeat-associated non-ATG 
(RAN) protein products. The protein products of these translations are polyGA, 
polyGR, polyPR, polyPA and polyGP. Protein aggregates containing some of the 
c9RAN has been detected in the cytoplasm and nucleus of neurons from C9orf72-ALS 
post-mortem tissue. The function of these proteins is unknown, nonetheless their 
expression is toxic and forms intracellular aggregates in a repeat length-dependent 
manner (Zhang et al., 2014). 
1.1.2.9.2 Mechanisms of protein aggregation 
The exact mechanism that causes protein aggregation and its involvement in the 
pathogenesis of ALS is still debated; however, several pathways can be suggested:  
Genetic defects 
Most SOD1 mutants showed increased vulnerability for hydrophobicity change 
under denaturation conditions. Increased hydrophobicity induces the formation of 
small aggregates, which grow in a time-dependent manner (Munch and Bertolotti, 
2010).    
Recently, ten mutations have been identified in SQSTM1 gene in ALS patients 
that occurred in highly conserved regions, and were predicted to have a deleterious 
effect on p62 structure and function by misfolding the protein, affecting its 
phosphorylation, protein-protein interactions or ubiquitination (Deng et al., 2011b).  
Two mechanisms were suggested for OPTN-dependent pathogenesis in ALS. 
Firstly, mutation in the DFxxER conserved motif of the OPTN inhibits its protein 
binding ability to ubiquitin and subsequently inability to inhibit the nuclear factor 
kappa B (NF-κB), which is known to play a critical role in cell development and 
survival (Pizzi and Spano, 2006). Secondly, OPTN is known to be involved in 
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intracellular trafficking and its mutation might cause disruption of this intracellular 
trafficking and subsequently cause its aggregation (Maruyama et al., 2010) 
Dephosphorylation 
Two separate research groups have identified phosphorylation specific sites on 
TDP43, which are serine residues 379, 403, 404, 409 and 410 (Li et al., 2011, van 
Eersel et al., 2011). They showed that the unphosphorylated models showed increased 
or unchanged aggregation and insolubility, while hyperphosphorylation caused 
significantly decreased aggregation and increased solubility in relation to the number 
of phosphorylation sites. Expression of Casein kinase 2 alpha (CK2α), which is known 
to induce phosphorylation, increased the TDP43 solubility and maintained the 
neuronal cell growth. Same results were observed using transgenic (TG) drosophila 
(Li et al., 2011). In agreement with that, oxidative stress to neuronal cells induced 
TDP43 phosphorylation but not aggregation. However, other stressors, including ER 
stress and proteasome inhibition, showed induced expression and cytosolic 
aggregation of both TDP43 and its phosphorylated form (Ayala et al., 2011). These 
results indicated that dephosphorylated TDP43 has a cytotoxic effect on cells. 
Therefore, it has been proposed that hyperphosphorylation is a defensive mechanism 
against TDP43 aggregation. However, it is noteworthy that the phosphorylation and 
ubiquitination occurs after aggregation (Li et al., 2011). 
Cytoplasmic translocation 
A study showed that stressors like oxidative stress, proteasome inhibition and ER 
stress induced the translocation of the 37kDa fragment of TDP43 to the cytosol. This 
translocation was found to be correlated with aggregates formation (Ayala et al., 
2011). Cellular stress has been shown to induce phosphorylation of the extracellular 
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signal-regulated kinase ERK1/2, a known kinase involved in many cellular processes 
including cell proliferation, growth, survival and gene transcription (Ayala et al., 2011, 
Cargnello and Roux, 2011) and inhibits transcription factors-nuclear import (Czubryt 
et al., 2000). However, inactivation of ERK1/2 leads to fragmentation of nuclear 
TDP43 and increased localisation of TDP43 in the cytosol whether the cells are 
stressed or not, which means that ERK1/2 is involved in regulation of TDP43 
homeostasis and TDP43 cytoplasmic aggregation occurs through some kinase 
pathway (Ayala et al., 2011).  
Interestingly, transfection of yeast cells with human FUS showed cytoplasmic 
localisation of FUS and this localisation was enough to form FUS aggregates and 
inclusions. Furthermore, induction of nuclear localisation of FUS by fusing a 
heterologous nuclear localisation signal (NLS) to the human FUS restricted its 
expression to the nucleus and was enough to eliminate its aggregation and cytotoxicity, 
which means that FUS cytoplasmic localisation is enough to induce its aggregation. It 
is noteworthy that ALS-linked FUS mutations are mostly in the C-terminus, more 
specifically in the NLS region (see figure 1.3). Collectively, these indicate that FUS 
aggregation is cytotoxic and its import defect might be involved in the pathogenesis 
of ALS. Despite the importance of NLS in nuclear localisation, some FUS constructs 
that lack NLS domain, surprisingly, showed predominant nuclear localisation. This 
means that a second hit, such as a second mutation or an environmental factor, might 
be needed for FUS redistribution and aggregation (Sun et al., 2011). 
 Proteasomal dysfunction 
The two main proteolytic machineries are the UPS and autophagy. UPS targets 
the degradation of soluble and short-lived protein, and it is the main degradation 
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pathway. On the other hand, autophagy is the bulk clearing mechanism, in which it 
targets cellular organelles, long-lived aggregated proteins. Both pathways competency 
declines with age. As ALS is mostly an adult-disease, it is reasonable to say that 
proteolytic dysfunction could be involved in the pathogenesis of ALS (Jansen et al., 
2014).   
It has been reported that inhibition of proteasome pathways in primary motor 
neurons causes redistribution of TDP43 to the cytoplasm and aggregation, while other 
cellular stressors had no effect on its distribution. This redistribution was accompanied 
by increased insolubility, molecular weight (~50kDa), ubiquitination and 
phosphorylation. TDP43 reduction makes the neurons vulnerable, and knocking down 
TDP43 increases their death. Therefore, it seems that TDP43 distribution is controlled, 
at least partly, by the proteasome system and that a first hit, such as TDP43 
dysfunction, increases the cell vulnerability and a second hit, such as proteasome 
dysfunction, induces neurodegeneration and vice versa (van Eersel et al., 2011).  
UBQLN2 might also take this approach for aggregation as it has been proposed to 
mediate ubiquitinated-protein degradation by delivering the poly-ubiquitinated 
proteins to the proteasomes (Ko et al., 2004). In addition, VCP has been found to 
immunoprecipitate with Dorfin, which is an ubiquitin-ligase (Ishigaki et al., 2004). In 
support of these findings, a recent study showed that UPS is the main cellular 
degradation tool for TDP43 that maintains its homeostasis. It has been shown that 
aggregates form in response to failure of UPS degradation pathway but not due to 
autophagy inhibition. When UPS is inhibited, the non-degraded TDP43 (both wild 
type and mutant) accumulate and become insoluble and targeted for autophagy 
degradation. However, autophagy is unable to compensate for the UPS deficiency, and 
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therefore aggregates form and toxic protein accumulate in the cell and induce cell 
death (Scotter et al., 2014). 
A further support for the importance of this pathway in the pathogenesis of ALS, 
the toxic effect and aggregation of c9RAN (polyGA) was found to be via disruption 
of UPS, which induce ER stress and apoptosis (Zhang et al., 2014).  
It is noteworthy that UPS and autophagy are connected pathways and share some 
modulators like UBQLN2, VCP, OPTN and p62, all have been reported to be mutated 
or involved in some ALS cases, which emphasize the importance of these pathways 
in ALS pathogenesis 
Prion-like property 
Prion diseases are neurodegenerative diseases that are characterised by formation 
of pathological prion protein aggregates, which are proteolysis-resistant and detergent 
insoluble. Prion proteins are expressed in several types of cells, including cells from 
the nervous system, and they are normally localised on the outer surface of the cell 
membrane (Linden et al., 2008). A recent study showed that upon ER stress or 
proteasome inhibition, prion proteins import into the cell and partially localise on 
Golgi compartments, where they cause the formation of detergent insoluble prion 
protein aggregates (Nunziante et al., 2011).  
The main structural characteristic of the disease-related prion proteins is their 
enrichment of β-sheets, unlike the normal prion proteins that are rich in α-helices. In 
disease, the α-helices undergo conformational changes to β-sheets that give them a 
protease resistance property (Baldwin et al., 1994, Biljan et al., 2012). Twenty out of 
thirty eight identified prion disease-related mutations and polymorphisms occurr in 
the α-helices regions. In addition, deletion and insertion mutations were identified in 
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the octapeptide (PHGGGWGQ) repeat region, which is also a glycine-rich domain 
(Biljan et al., 2012)   
Three ALS-related proteins showed similar properties to prion proteins (Figure 
1.3). Firstly, the C-terminus of TDP43 shares similarity with prion proteins in the 
composition of glutamine- and asparagine-rich and can execute conformational 
changes that cause inactivation and aggregation of the protein (Baloh, 2011, Guo et 
al., 2011). Purified soluble TDP43 is inherently aggregation-prone and highly prone 
to conformational changes. In accordance with that, flies transfected with either wild 
type TDP43 (WT-TDP43) or its mutants showed developmental abnormality, 
movement defect, axonal swelling, disorganised motor neuron clusters and neuronal 
loss, which show the toxic effect of overexpression of both WT-TDP43 and its mutants 
(Guo et al., 2011). Transfection of human embryonic kidney cells (HEK293) with WT-
TDP43 or mutant TDP43 showed that only mutant TDP43 causes the formation of 
detergent insoluble, heat-stable and urea denaturation-resistant high molecular weight 
phosphorylated aggregates that are ubiquitin-negative (Guo et al., 2011). 
It is suggested that the C-terminal domain of TDP43 constituting of 45a.a, which 
contains the prion-like domain, can form an extended β-sheet. This conformation is 
enhanced by mutating the alanine residue 314 to threonine (A314T), which explains 
the neurotoxicity in A314T mutants (Guo et al., 2011). Accordingly, omitting the C-
terminus maintained the solubility of the protein while deleting the N-terminal showed 
protein aggregation that is similar to the full-length protein. This indicates that the C-
terminus is critical for protein aggregation (Johnson et al., 2009). Furthermore, 
HEK293 and neuronal cells transfected with TDP43 with N-terminal deletion showed 
more tendencies for aggregation (Li et al., 2011).  
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It is noteworthy that all TDP43 mutations that are associated with ALS/FLTD 
occur at the C-terminus except one that occurs in the RNA binding domain (Baloh, 
2011, Sun et al., 2011).  
In addition, FUS shares some similarity with TDP43 but unlike TDP43, FUS 
consist of two prion-like domains; one is present at the N-terminus and the other one 
at the first arginine-glycine-glycine (RGG) repeat region (Figure 1.3). Both prion-like 
domains in addition to the RNA-recognition motif (RRM) domain are necessary to 
induce protein aggregation and toxicity in yeast and mammalian cells (Sun et al., 
2011). 
It has been shown that mutated SOD1 in some FALS cases and misfolded WT 
SOD1 in a subset of SALS cases undergo conformational changes and hence cause 
neurotoxicity (Chattopadhyay and Valentine, 2009, Bosco et al., 2010). It is 
noteworthy that although SOD1 contain only one domain; i.e. the  Copper/Zinc 
superoxide dismutase  domain, the protein structure is β-sheet enriched (Moreira et 
al., 2013). In addition, ALS-related SOD1 mutations mostly occur in the β-sheets and 
most of the mutations cause conformational changes in the protein (Orrell, 2000).  
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Figure 1.3: Comparison between Prion, TDP43, FUS and SOD1 proteins 
domains. The differences and similarities between the TDP43 and FUS domains with 
the prion protein domains are presented. The reported mutation sites in prion disease 
and ALS are presented as bars above the protein domains. SP; signal peptide. OR; 
octapeptide repeats region. α; α-helix structure. β; β-sheets structure. G-rich; Glycine 
rich. RRM; RNA-recognition motif. NLS; nuclear localisation signal. NES; nuclear 
export signal. Q; glutamine. G; glycine. S; serine. Y; tyrosine. N; asparagine. RGG; 
arginine-glycine-glycine repeat (Kozin et al., 2001, Millhauser, 2007, DeJesus-
Hernandez et al., 2010, Baloh, 2011, Gitler and Shorter, 2011, Sun et al., 2011, Biljan 
et al., 2012) 
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The results of those studies show that SOD1, TDP43 and FUS share prion-like 
properties that may provide them with aggregation ability that is involved in ALS 
pathogenesis. In addition, prions reproduce by interacting with the normal endogenous 
prion protein and provoke conformational changes to that normal protein. This might 
give a clue about how ALS starts in specific cells or locations and spreads to other 
parts (Polymenidou and Cleveland, 2011).  
Recent evidence supports the concept of prion-like propagation of misfolded 
protein aggregates in different proteinopathies including ALS. Results from 
pathological studies as well as neuroimaging studies on neurodegenerative diseases 
support the idea of disease spread along structural brain connections. It was shown 
that aggregate formation and neurodegeneration starts at specific areas of the brain 
and progresses through predicted anatomical connections in which misfolded 
aggregates spread by transsynaptic or transneuronal connection between brain areas 
(Guo and Lee, 2014, Verstraete et al., 2014, Agosta et al., 2015). Despite the lack of 
in vivo studies, in vitro evidence showed that mutant SOD1 and TDP43 can exhibit 
prion like properties (Chen et al., 2010, Munch et al., 2011, Nonaka et al., 2013). It 
was shown that inoculation of mutant SOD1 or TDP43 aggregates, which were either 
produced from recombinant proteins or extracted from ALS-brain lysates, into the 
culture media lead to their uptake by the cells. The exongenous aggregates worked as 
seeds that induce aggregation of endogenous, originally soluble, proteins (Chia et al., 
2010, Munch et al., 2011, Nonaka et al., 2013).  
These studies indicate the involvment of protein aggregates in the progression of 
the disease. However, the exact cause that induces formation of the first aggrgate “the 
seed” is still unclear. Interestingly, Munch and colleagues showed that the seeding 
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capability of mutant SOD1 aggregates is only effective when soluble mutant SOD1 is 
expressed endogenously. When aggregates are introduced to cells expressing WT 
SOD1, the seeding effect was not observed (Munch et al., 2011). This could support a 
two hit hypothesis, in which first induction of protein aggregation and second genetic 
mutation, serve as factors that increase the susceptibility for neurodegeneration.  
In summary, the exact mechanism of ALS pathogenesis is still debated. It has been 
suggested that two or more hits, for example environmental factors and genetic 
mutation, are needed to develop the disease (Swarup et al., 2011, Field et al., 2013). 
Therefore, it is essential to understand the mechanisms involved in the pathogenesis 
of ALS more in order to find a better treatment. Otherwise, a treatment targeting 
different aspects of the disease needs to be developed. 
1.2 ADP-ribosylation factor-interacting protein (Arfaptin2) 
1.2.1 Structure  
Arfaptin2, also known as partner of Rac1 (POR1), is a protein consisting of 341a.a 
with a molecular weight of ~38.6 kDa that is ubiquitously expressed in different types 
of cells. Arfaptin2 contains a leucine zipper in its N-terminus, which gives it a high 
positive charge that might allow it to bind to DNA. The C-terminus contains the 
Bin/amphiphysin/Rvs (BAR) domain, which is present in different proteins that are 
involved in membrane curvature (Kanoh et al., 1997, Peter et al., 2004).  
1.2.2 Function  
 The exact function of Arfaptin2 is still unknown. However, one can speculate its 
function by knowing its interaction with known proteins (Table 1.2). Arfaptin2 
interacts with the ADP-ribosylation factor (Arf) family proteins and Rac1 protein, 
which both are subfamilies of small GTPases (Ras superfamily). GTPases 
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continuously recycle between GTP-bound (active) state and GDP-bound (inactive) 
state and exert many cellular functions (Figure 1.4).  
ARFs are GTP-binding proteins that are involved in intracellular vesicular 
transport including formation of coated vesicle and cytoskeletal reorganisation 
(Serafini et al., 1991, D'Souza-Schorey et al., 1997, Man et al., 2011) and 
transportation between the ER and Golgi (Balch et al., 1992, Kanoh et al., 1997).  
Rac1 is a small GTP-binding protein from the Rho subfamily. It is involved in 
membrane ruffling and actin cytoskeleton rearrangement (Ridley et al., 1992), 
generation of superoxide, transformation of oncogenic cells and activation of 
transcription factors in a GTP-dependent manner. Rac has 3 isoforms, in which Rac1 
is ubiquitously expressed and is the mostly studied isoform, Rac2 is hematopoietic 
cells specific and Rac3 is CNS specific. Rac1 is important for foetal development as 
Rac1 knockdown is embryonic lethal (Sugihara et al., 1998, Corbetta et al., 2005).  
In Neuroblastoma cells, Rac1 is involved in growth cone dynamics. Rac1 loss of 
function mutations caused axonal growth defects in Drosophila (Hakeda-Suzuki et al., 
2002, Ng et al., 2002). On the other hand, Rac1 activation in dorsal root ganglion 
decreases neurite out growth. In addition, it is involved in induction of apoptosis in 
neuroblastoma cells treated with metformin, a treatment that decrease cancer growth 
(Kumar et al., 2014). These might indicate a differential functions of Rac1 dependent 
on cell types and its involvement and regulation of apoptosis (Stankiewicz and 
Linseman, 2014).  
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Figure 1.4: Ras superfamily GTPases classification and activation. a) Ras 
superfamily consist of over 100 molecules, which are subdivided based on homology 
into 9 subtypes. Rho consists of over 30 proteins of which 3 are most studied (RhoA, 
Cdc42 and Rac1). Arf family consists of two subtypes, which are Arf and Arf-like (Arl) 
proteins. b) GTPases are activated by guanine-nucleotide exchange factor (GEF) and 
deactivated by GTPase-activating protein (GAP). 
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Arfaptin2 binds to GTP-bound Rac1, which is the active form. Transfection of 
fibroblasts with the C-terminus half of Arfaptin2 (HC-ARFIP2) caused inhibition of 
Rac1-induced membrane ruffling (Van Aelst et al., 1996), which indicate that FL-
ARFIP2 activates Rac1 while HC-ARFIP2 inhibits it. The HC-ARFIP2 in this study 
is formed of the last 705bp of Arfaptin2 sequence. In contrast, another study showed 
that Arfaptin2 binds strongly to GDP-bound Rac1 but not GTP-bound Rac1, while it 
binds preferentially with GTP-bound ARFs, especially Arf1, Arf5 and Arf6 in Chinese 
hamster ovary cell line (Shin and Exton, 2001). This controversy could be due to the 
use of different cell types or the fact that Arfaptin2 was lacking 114-nucleotide from 
the N-terminal in Van Aelst experiments compared to the full-length Arfaptin2 used 
in Shin and Exton study.  
Arfaptin2 is normally expressed as a cytoplasmic protein that predominantly 
localises to the perinuclear region and is associated with the microtubule-organising 
centre, and colocalises with the trans-golgi marker (TGN46) (Peters et al., 2002, Peter 
et al., 2004, Rangone et al., 2005, Man et al., 2011). This association is facilitated by 
small GTPases and phosphatidylinositol-4-phosphatase (PI(4)P) (Cruz-Garcia et al., 
2013). 
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Table 1.2: A list of molecules interacting with Arfaptin2 and their functions. 
Molecule Function  Reference  
Rac1 Membrane ruffling, actin cytoskeleton 
rearrangement and regulate ROS 
production and apoptosis 
(Ridley et al., 1992, 
Suzukawa et al., 2000, 
Kumar et al., 2014)  
Arf1-6 Vesicle trafficking, recruit effectors to 
the Golgi apparatus, and cytoskeleton 
organisation  
(Serafini et al., 1991, 
D'Souza-Schorey et al., 
1997, Gillingham and 
Munro, 2007, Man et al., 
2011) 
Arl-1 Formation of endosomes, endosome-to-
Golgi trafficking, and trans Golgi 
network protein sorting 
(Van Valkenburgh et al., 
2001, Burd et al., 2004) 
PI(3)P Endosome-derived transport vesicles, 
autophagy, trans Golgi network protein 
sorting, and cytokinesis 
(Cruz-Garcia et al., 2013, 
Schink et al., 2013) 
PI(4)P Vesicular trafficking, ER export, 
autophagy, cytokinesis and actin 
cytoskeleton rearrangement. 
(Cruz-Garcia et al., 2013, 
De Matteis et al., 2013) 
PI(5)P Induce apoptosis, actin cytoskeleton 
rearrangement, vesicular trafficking and 
glucose maintenance.  
(Cruz-Garcia et al., 2013, 
Shisheva, 2013) 
 Table obtained from (Mohammedeid et al., 2014) with permission. 
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1.2.3 Arfaptin2 in neurodegenerative diseases 
Only a couple of research groups have studied the involvement of Arfaptin2 in 
neurodegeneration. However, similar to its function, Arfaptin2 involvement in 
neurodegenerative diseases can be speculated by understanding the roles of the 
molecules interacting with Arfaptin2 in neurodegenerative diseases.  
Mounting evidence demonstrates the importance of Rac1 in neuronal 
development and survival (Tahirovic et al., 2010, Stankiewicz and Linseman, 2014). 
For instance, Fasudil is a Rho kinase (ROCK) inhibitor. Takata et al. showed that 
fasudil and another Rho inhibitor (Y-27632) have neuroprotective effects on NSC34 
overexpressing SOD1G93A. They showed that SOD1G93A expression in NSC34 
induces PTEN phosphorylation and decreases Akt phosphorylation and this effect can 
be reversed via inhibition of ROCK by fasudil (Takata et al., 2013). Furthermore, it 
has been shown that fasudil delayed the disease onset by approximately 10% in 
SOD1G93A mice and extended the life span by 6%. In addition, Fasudil treatment 
decreased motor neuron loss in SOD1G93A mice compared to WT and non-treated 
animals (Takata et al., 2013, Tonges et al., 2014). This protective effect was through 
inhibition of ROCK and hence mitigating the decreased Akt phosphorylation caused 
by SOD1G93A expression (Takata et al., 2013, Tonges et al., 2014). 
It is noteworthy that although Rho and Rac fall in the same Rho subfamily, Rho and 
Rac GTPases work in a reverse manner, in which Rac has a pro-survival effect and 
Rho has a pro-apoptotic effect (Stankiewicz and Linseman, 2014). Similarly, Rac 
induced growth cone dynamics while Rho decreases it in neuronal cell line (NG108-
15) and in primary neurons (Jain et al., 2004). The prosurvival effect of Rac is believed 
to be through two pathways, which are PI3K/Akt pathway and PAK/ERK pathway.  
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In support of the importance of Rac1 in neuronal survival, Alsin protein contains 
a GEF domain that activates Rac1 (Kanekura et al., 2005) and Rab5 (Otomo et al., 
2003). ALS-related mutations to alsin gene produce a truncated Alsin protein that 
causes disruption to Rac1 activity and induce cell death. In addition, SOD1G93A-
induced neurodegeneration in NSC34 was reversed by overexpression of Alsin. 
Furthermore, Rac1 knock down by siRNA reversed the neuroprotective activity of 
Alsin overexpression and induced cell death (Kanekura et al., 2005). Further support 
was provided by (Jacquier et al., 2006) as they showed that Alsin is crucial for motor 
neuron survival and axonal growth in a Rac1-dependent manner.  
Another Rac1 activating factor that is involved in ALS pathogenesis is 
ARHGEF16, which is downregulated in post-mortem spinal cord tissues from SALS 
patients (Figueroa-Romero et al., 2012). 
The involvement of other GTPases in neurodegeneration also has been suggested. 
Structural bioinformatics showed homology between C9ORF72 protein product and a 
known Rab GEF called differentially expressed in normal and neoplasia (DENN). Rab 
is involved in membrane trafficking (Levine et al., 2013). They suggested that C9orf72 
is involved in ALS pathogenesis by binding to Rab and disturbing endosomal 
trafficking or autophagy. 
Huntington’s disease (HD) is a devastating neurodegenerative disease that is 
caused by a pathologic polyglutamine repeat expansion in huntingtin gene (polyQ-
huntingtin). The polyQ-huntingtin pathogenic effect is through disruption of 
proteasomal activity (Jana et al., 2001). Arfaptin2 has been found to colocalise with 
huntingtin aggregates in HD cell models. Both full length and the N-terminus of 
Arfaptin2 induced polyQ-huntingtin aggregation in neuronal cells but expression of 
Chapter 1: Introduction 
36 
 
 
the C-terminal of Arfaptin2 (HC-ARFIP2) showed extensively decreased aggregate 
formation. This aggregation inhibition was found to be through the proteasome 
pathway, as inhibition of proteasome pathway by lactacystin reversed the inhibitory 
effect of HC-ARFIP2 (Peters et al., 2002). In addition, Arfaptin2 expression was found 
to be increased in the brain of HD mouse (Peters et al., 2002) and patients (Rangone 
et al., 2005). Arfaptin2 has been found to retain the proteasome function in HD cell 
models (Peters et al., 2002, Rangone et al., 2005). Therefore, two hypotheses were 
raised. Firstly, Arfaptin2 is involved in the pathogenesis of HD by inhibiting the 
proteasome function, whereas its truncated HC-ARFIP2 form works as a negative 
modulator for the Arfaptin2 (Peters et al., 2002). Secondly, Arfaptin2 is a defence 
protein that, when phosphorylated, retains the proteasome function and inhibits protein 
aggregation. It was also suggested that protein aggregates act as both inhibitors and 
products of UPS inhibition (Rangone et al., 2005).  
Another study showed that phosphorylated Arfaptin2 at serine residue 260 
(Ser260) can reduce huntingtin aggregation. Insulin-like growth factor 1 decreases the 
PolyQ-huntingtin neurotoxic effect through phosphorylating Akt (phospho-Akt), 
which is a prosurvival kinase. The phosphorylated Akt in turn phosphorylates the 
polyQ-huntingtin. However, Akt has been shown to have another pathway for 
inhibiting the polyQ-huntingtin neurotoxic effect that is huntingtin phosphorylation-
independent. Neuronal cells transfected with huntingtin that contain the pathologic 
polyQ expansion but lack the phosphorylation site showed significantly induced 
survival and decreased intracellular inclusion formation after treatment with phospho-
Akt. It has been shown that phospho-Akt phosphorylates the full-length Arfaptin2 at 
Ser260. The de-phosphorylation of Arfaptin2 by mutating Ser260 causes its 
redistribution from the perinuclear region to form a network structure throughout the 
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cytoplasm in a microtubule-dependent manner. In addition, primary striatal neuron 
cultures from HD embryonic rats were double transfected with Arfaptin2 and an active 
form of Akt which showed that Arfaptin2 was phosphorylated by Akt leading to 
significant increase in survival and decreased protein inclusion formation. This 
survival was decreased when cells were transfected with a mutant dephosphorylated 
form of Arfaptin2 (Rangone et al., 2005). It is noteworthy that Ser260 is localised in 
the C-terminal part of Arfaptin2. The concept of Arfaptin2 involvement in protein 
aggregation in Huntington’s disease is summarised in figure 1.5. 
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Figure 1.5: A Schematic presentation of possible involvement of Arfaptin2 in 
protein aggregation. Figure adapted from (Mohammedeid et al., 2014) with 
permission.  
Chapter 1: Introduction 
39 
 
 
1.3 Hypothesis  
Previous studies (Peters et al., 2002, Rangone et al., 2005) showed that Arfaptin2 
regulates proteasome activity and protein aggregation in HD. A recent study showed 
that cytoplasmic inclusions that are immunoreactive for TDP43 coexisted with 
huntingtin aggregates in two HD cases that developed ALS (Tada et al., 2012). 
Although huntingtin-immunoreactive inclusions did not colocalise with TDP43 
immunoreactive inclusions, their coexistence in some neurons in the spinal cord and 
motor cortex indicates that aggregation of huntingtin in HD and TDP43 in ALS might 
have a common pathway. In addition, the presence of TDP43-immunoreactive 
aggregates in those cases was associated with motor neuronal loss. 
Accordingly, based on the finding that full-length Arfaptin2 inhibits proteasome 
activity and dominant negative form of Arfaptin2 (HC-ARFIP2) activates proteasome 
activity (Peters et al 2002), we hypothesise that HC-ARFIP2 expression or Arfaptin2 
knockdown reduces protein aggregation in ALS via maintaining the proteasomal 
pathway, which in turn decreases neuron toxicity and improves neuronal survival. 
1.4 Aims of the project 
The aim of the project is to investigate the effect of Arfaptin2 on protein 
aggregation and neuronal survival in in vitro and in vivo ALS models. In addition, we 
aim to investigate downstream effectors of Arfaptin2/HC-ARFIP2 to identify their 
targeted pathway and how it correlates with neuroprotection. These would provide 
evidence whether Arfaptin2 is a possible target for therapeutic intervention in ALS. 
Lentiviral constructs expressing FL-ARFIP2 or HC-ARFIP2 genes were 
generated in order to over-express the proteins efficiently in vitro. Subsequently, cells 
were transduced with the virus and the levels of protein expression were determined 
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by immunoblotting technique. Finally, FL-ARFIP2 and HC-ARFIP2 will be 
subcloned into self-complementary adeno-associated virus serotype 9 (scAAV9) to 
increase the transduction efficiency via systemic delivery to mouse models of ALS. 
This will be the tool to investigate the effect of FL-ARFIP2 or HC-ARFIP2 expression 
on protein aggregation in motor neurons and survival in ALS mouse model. 
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2.1 Materials  
2.1.1 Molecular techniques materials 
All competent cells were purchased from STRATAGENE unless otherwise 
specified. All plasmid preparation and gel extraction kits were purchased from 
QIAGEN.  
All primers for PCR were purchased from Sigma. All restriction enzymes and 
buffers were purchased from NEB. 
Western blot tools, i.e. power supplies, tanks, glass plate, protein ladder and pre-
cast gels, were purchased from BIO-RAD. 
2.1.2 Common solutions and buffers 
Analytical grade solvents ethanol, methanol and isopropanol, and acids were purchased 
from Fisher Scientific. Nuclease free water (NF-H2O) was purchased from Ambion. Pipette 
tips were purchased from Fisher Scientific. Components for western blot solutions were 
purchased from Sigma except beta-mercaptoethanol (β-ME) that was purchased from 
Invitrogen. 
Tris-acetate-EDTA (TAE) buffer 
40 mM Tris base, 20mM glacial acetic acid and 1mM EDTA 
Separating gel buffer 
375 mM Tris base and 0.1% SDS in deionized water (dH2O), pH 8.8 
Stacking gel buffer 
125 mM Tris base and 0.1% SDS in dH2O, pH 6.8 
4x Laemlli sample buffer 
4 ml glycerol, 2 ml 10% SDS, 0.25 mg bromophenol blue, 2.5 ml stacking gel buffer and 
0.5ml β-ME in 10 ml dH2O 
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5 x Tris-glycine buffer 
25 mM Tris base, 0.2 M glycine in dH2O 
Tris-buffered saline and Tween (TBST) 
0.137 M NaCl, 25.92 mM Tris base, 0.1% Tween 20, pH 7.6 
Phosphate buffered saline (PBS) 
Provided as tablets from Sigma, one tablet dissolved in 200 ml dH2O 
4% Paraformaldehyde (PFA) 
4% (w/v) PFA (Sigma) in 100 ml PBS 
Western bolt running buffer 
25 mM Tris base, 192 mM Glycine, 0.1% SDS and made up to volume with dH2O 
Lysis buffer (RIPA) 
50 mM Tris-HCl (pH 7.4), 1% NP-40, 0.5% Na deoxycholate, 0.1% SDS, 150 mM NaCl, 2 
mM EDTA and made up to volume with dH2O 
5x Transfer buffer  
125 mM Tris base, 960 mM Glycine and made up to volume with dH2O 
2x Hank’s buffered salt solution (HBSS) 
280 mM NaCl, 100 mM HEPES, 1.5 mM Na2HPO4, pH 7.1 
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2.1.3 Cell lines and cell culture 
Tissue culture flasks and plates were purchased from Thermo Scientific unless 
otherwise specified.  
A stock of HEK293T cells (human embryonic kidney cell line expressing the large 
T antigen from SV40 virus) in 5% dimethyl sulfoxide (DMSO) was stored in a liquid 
nitrogen chamber. HEK293T cells were maintained in full medium that is made of 
Dulbecco’s modified eagle medium (DMEM) (with 45 g/L glucose, L-glutamine 
without Na Pyruvate, Lonza BE12741F or Sigma D5796) with 10% heat inactivated 
foetal bovine serum (FBS) (Biosera, S1900500) and 1% penicillin/streptomycin 
(pen/strep) (10000 U/ml, 110000 µg/ml, Sigma, P0781). To thaw the cells, a vial of 
cells was thawed for 1 min at 37 º C in a water-bath, rapidly suspended in 10 ml of 
HEK293T full medium, and centrifuged at 500xg for 5 min. The supernatant was 
discarded and the cell pellet resuspended in 10 ml full medium, cultured in a T75 flask, 
and incubated at 37˚C with 5% CO2 in an incubator. To passage the cells, the medium 
was removed and cells were washed with 10 ml PBS. Cells were detached by addition 
of 2 ml trypsin consisting of 0.053 mM EDTA and 0.005% trypsin in HBSS (Sigma, 
H8264). The detached cells were resuspended in full medium and split in to four T175 
flasks.  
Primary motor neurons were maintained in primary motor neurons full medium 
that was made of Neurobasal-A medium (NB medium) (GIBCO, 10888-022) 
supplemented with 1% glutamax (GIBCO, 35050), 2% (v/v) horse serum donor 
(Linaris, SHD3250YK), 2% B-27 supplement (GIBCO, 12587-010) and 0.2µM β-
ME). 
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2.2 Methods 
2.2.1 Plasmid DNA isolation preparation 
Arfaptin2 and HC-ARFIP2 were expressed in the pcDNA3 vector with ampicillin 
resistance property, which were kindly provided from Dr Crislyn D’Souza-Schorey 
(University of Notre Dame, Notre Dame, Indiana, USA). HC-ARFIP2 is the C-
terminal part of ARFIP2 from base 510-1026. The WT-TDP43 was expressed in 
pDONR221 vector with kanamycin resistance gene (Peters et al., 2002). They were 
kindly provided by Dr Aaron D. Gitler (University of Pennsylvania, Philadelphia, 
USA). Stocks of bacterial cells expressing those vectors were kept in 15% glycerol at 
-80°C. Bacterial cells were inoculated in LB Broth (LBb) (Merck Millipore, 
1102850500) with the suitable antibiotic (Table 2.1). 
Plasmid DNA was extracted using either QIAprep Spin Miniprep Kit or QIAGEN 
Plasmid Plus Mega Kit, depending on the volume of the culture, following the 
manufacturer’s protocol. 
Plasmid size and purity were detected by loading the samples with DNA loading 
buffer blue (Bioline, bio37045) on 1% (w/v) agarose gel (MELFORD, MB1200) in 
100ml TAE buffer  with 0.5µg/ml ethidium bromide (Sigma-Aldrich, E1510). 
Samples were loaded and electrophoresed in TAE buffer at 140V for ~30minutes 
(min) using PowerPac 300. The gel pictures were taken using GENi system 
(SYNGENE, 12834038) 
Nucleic acid concentrations were measured using the Nanodrop 
spectrophotometer (Labtech) with the ND-1000 v3.2.1 software.  
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Table 2.1: List of antibiotics and their concentrations used in bacterial cultures 
Antibiotic Concentration Supplier  
Carbenicillin (Carb) 
(substitute for Ampicillin) 
50µg/ml Sigma, C3416 
Kanamycin  50µg/ml Sigma, K4000 
 
2.2.2 Transformation of XL1-Blue cells with Sin-LV-GDNF scAAV-CMV-GFP or 
plasmids for stock 
XL1-blue Escherichia coli (E.coli) competent cells were transformed with Sin-
PGK-cPPT-GDNF plasmid (Nicole Deglon, CEA Paris, France) (Lentivirus (LV) 
plasmid) (Figure 2.1) or scAAV-CMV-GFP (self-complementary adeno-associated 
virus (scAAV) plasmid) (figure 2.2) for stock preparation following the 
manufacturer’s protocol with some amendments. Briefly, the XL1-blue cells were 
thawed on ice and an aliquot of 50µl of cells was placed in a pre-chilled 14-ml BD 
Falcon polypropylene round-bottom tube (BD Falcon, 352059). A 0.1-50ng of LV-
plasmid was added to the cell aliquot and incubated on ice for 20min. Cells were heat-
shocked at 42ºC for 45seconds (sec) and returned to the ice for 2min. A 0.9ml of 
preheated (42ºC) Super Optimal broth with Catabolite repression (S.O.C) medium 
(Sigma-Aldrich, S1797) was added to the transformed cells. The cell suspension was 
incubated at 37ºC with shaking at 225rpm for 30min. Approximately 200µl of cell 
suspension was spread on LB agar plate (Fisher Scientific, BP1425500) containing 
Carbenicillin (LBa/Carb). The culture was incubated overnight at 37ºC.  
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Figure 2.1: Plasmid map of SIN-PGK-cPPT-GDNF plasmid. Produced by 
PlasMapper version 2.0  
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Figure 2.2: A plasmid map of scAAV-CMV-EGFP. Produced by PlasMapper version 
2.0 
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2.2.3 Amplification of DNA fragments by polymerase chain reaction 
A 50µl of PCR mix was prepared by mixing 1µl of DNA template, 1µl of 5µM of 
each primer; forward and reverse; 10µl of FIREPol 5x Master Mix Ready to Load with 
7.5 mM MgCl2 (Solis Biodyne, 041200115) and topped up with NF-H2O. The PCR 
reaction was performed using a GS2 thermal cycler (G-Storm). The temperature was 
set at 95ºC for 3min then each cycle was started with denaturation at 95ºC for 30sec, 
annealing at 60ºC for 30sec and elongation at 72ºC for 30sec, and DNA was amplified 
in 35 cycles. An extra elongation period for 7min at 72ºC was made and finally held 
at 4ºC. DNA templates and primers sequences from Sigma are listed in table 2.2. 
PCR products were loaded onto 1% agarose gel and electrophoresed at 140V for 
~30min. The desired DNA bands were extracted and purified using QIAquick Gel 
Extraction Kit following the manufacturer’s protocol. PCR products were either 
digested and used directly in the subcloning or cloned into TOPO TA to increase the 
subcloning efficiency. 
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Table 2.2: List of DNA templates and primers used for PCR 
DNA 
template 
Desired 
gene 
Forward primer Reverse primer 
pCDNA3-
Arfaptin2 
FL-
ARFIP2 
GTCTCAGATCTGCCACCA
TGACGGACGGGATCCTA 
ATAATCTCGAGTCAAGCGT
AATCTGGAACATCGTATGG
GTACTGCTCCTCTAGCCAG
G 
pCDNA3-
HC-
ARFIP2 
HC-
ARFIP2 
GTCTCGGATCCGCCACCA
TGCTCAGCCAGAAGT 
pDONR221
-TDP43 
TDP43 GGATCCGCCACCATGTCT
GAATATATTCGG 
CTCGAGCTACATTCCCCAG
CCAGA 
For scAAV subcloning 
pCDNA3-
Arfaptin2 
Arfaptin
2 
GTCTCACCGGTGCCACCA
TGACGGACGGGATCCTA 
ATAATTCTAGATCAAGCGT
AATCTGGAACATCGTATGG
GTACTGCTCCTCTAGCCAG
G 
pCDNA3-
HC-
ARFIP2 
HC-
ARFIP2 
GTCTCACCGGTGCCACCA
TGCTCAGCCAGAAGT 
pDONR221
-TDP43 
TDP43 GTCTCACCGGTGCCACCA
TGTCTGAATATATTCGG 
ATAATTCTAGACTACATTC
CCCAGCCAGA 
 
 In bold is BglII. BamHI is bold and underlined. In Bold and italic is the XhoI. In bold italic 
and underlined is the AgeI. XbaI is Italic and underlined. Underlined is the Kozak sequence. 
HA-tag is highlighted.  
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2.2.4 Subcloning of viral vector plasmids 
The principle of the subcloning is explained in figure 2.3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Schematic presentation of subcloning principle. Genes of interest 
were produced by PCR from known plasmids. The PCR products then were 
ligated to TOPO vector to express the restriction sites. TOPO vectors were then 
digested with restriction enzymes to extract the gene of interest. The target viral 
genome was also digested using the same restriction enzymes to linearize the 
plasmid to allow the gene of interest to ligate into the viral backbone using DNA 
ligase. 
Chapter 2: Materials and Methods 
52 
 
 
2.2.4.1 TOPO TA cloning and TOP10 cell transformation 
  PCR products were cloned into One Shot TOP10 chemically competent cells 
(Invitrogen, C4040-03), using the TOPO TA cloning kit (Invitrogen, K4500-01) 
following the manufacturer’s protocol. Briefly, a TOPO reaction mix was prepared by 
mixing ~10ng of purified PCR product, 1µl of salt solution (included in the kit) and 
50ng of TOPO vector (pCR 2.1-TOPO included in the kit). The mix was incubated for 
1hour at room temperature (RT). A further incubation period was performed overnight 
at 4ºC to increase the yield number of colonies. 
A LBa/Carb plate was spread with 40µl of 40mg/ml X-gal (5-Bromo-4-chloro-3-
indolyl-β-D-galactoside) (MELFORD, 7240-90-6) and warmed at 37ºC. The X-gal 
was used for white/blue selection and the 40mg/ml stock was prepared by dissolving 
200mg of X-gal in 5ml N,N-dimethylformamide (DMF) (Sigma-Aldrich, 319937) in 
a glass bottle covered with foil and stored at -20ºC. 
TOP10 competent cells were transformed with 4µl of the TOPO reaction mix, 
incubated on ice for 5min then heat shocked at 42°C for 30sec, and cooled immediately 
on ice. A 250µl of S.O.C medium was added and incubated at 37°C with continuous 
shaking at 225rpm for 1hour. A 50µl of transformed cells was spread on the pre-
warmed LBa/Carb-X-gal and incubated overnight at 37ºC. 
2.2.4.2 Plasmid extraction and analysis by restriction enzymes 
 Successful transformations were analysed by extracting plasmid DNA from the 
cells of several colonies using the plasmid miniprep kit as mentioned above. The 
plasmids were analysed by restriction enzymes following the manufacturer’s protocol. 
Briefly, up to 3µg of the extracted plasmid DNA was digested by mixing it with 2µl 
of 10xBSA (bovine serum albumin), 2µl NEBuffer (depends on the restriction 
enzymes compatibility), 0.5µl of each restriction enzyme and topped up with NF-H2O 
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to get a total of 20µl mix. The digestion mix was incubated at 37ºC for 2 hours. The 
digestion mix was mixed with DNA loading buffer blue and loaded on 1% agarose gel. 
The samples were electrophoresed as mentioned above. Successful insertion of the 
fragment was further confirmed by sequencing. 
2.2.4.3 Extraction of the desired DNA and ligation to virus-backbone 
 Once the subcloning of the desired DNA in the TOPO plasmid was confirmed, 
plasmids (LV-plasmid, TOPO, scAAV-plasmid and PCR products) were digested 
with corresponding restriction enzymes and electrophoresed on 1% agarose gel. The 
desired bands corresponding to the LV-backbone, scAAV-backbone and the target 
DNA inserts were extracted and purified using the QIAquick Gel Extraction Kit. The 
purified viruses’ backbones and the inserts were ligated using T4 DNA ligase (NEB, 
M02025) following the manufacturer’s protocol with minor modifications.  
Briefly, the required concentration of the insert was calculated using the equation: 
 
Weight of insert (ng)=weight of vector (ng)x 
size of insert (Kbp)
size of vector (Kbp)
 x molar ratio
insert
vector
. 
30ng of vector was used and the vector: insert ratios were 1:3 and 1:5. The 
size of LV-backbone is 8.8kbp and the scAAV-backbone is 3.9kbp. A ligation mix 
of 2µl T4 DNA ligase, 30ng of LV vector, the required weight of insert, 1µl of T4 
DNA ligase and the volume was topped up to 25µl with NF-H2O. The ligation mix 
was incubated overnight at 4ºC. 
2.2.4.4 Transformation of XL10-Gold competent cells with the ligated DNA 
The ligated construct was transformed into XL10-Gold cells following the 
manufacturer’s protocol. Briefly, cells were thawed on ice and 50µl was aliquoted into 
pre-chilled 14ml BD falcon polypropylene round-bottom tubes. 2µl of β-ME provided 
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in the kit was added to the cells and incubated on ice for 10min with periodic swirling. 
2µl of the ligation mix was added and incubated on ice for 30min. The cells were heat 
shocked at 42ºC for 30sec then cooled on ice for 2min. Preheated SOC medium 
(0.9ml) was added and the cells were incubated at 37ºC for 1 hour with vigorous 
shaking. 200µl of cells was placed on LBa/Carb plate and incubated overnight at 37ºC. 
Successful transformations were checked by plasmid extraction and digestion as 
mentioned above and confirmed by sequencing. Plasmid megapreps of the ligated 
construct from the transformed XL10-gold cells were prepared and stored at -20ºC. 
2.2.5 Validation of LV- and scAAV-based plasmid vectors by transfection and 
western blot 
2.2.5.1 HEK293T cells culture 
The cells were plated on 6-well plate at a density of 200,000 cells/well on the day 
prior to transfection. The medium was changed 2 hours prior to transfection. A stock 
of 1mg/ml Polyethylenimine (PEI) (Polysciences, 24765) was prepared in sterile PBS. 
Transfection mix was prepared by diluting 2µg of DNA/well in water containing PEI 
in which the PEI:DNA ratio is 3:1w/w. The mixture was left at RT for 15min then was 
added to the wells. The cells were incubated for 3 days. 
2.2.5.2 Protein extraction 
The medium was removed, and the cells were washed once with 1ml PBS. Cells 
were scraped with sterile cell scraper and resuspended in 1ml PBS. Cells were 
centrifuged at 500xg for 5min. The cell pellet was lysed with nuclear and cytoplasmic 
lysis buffer (0.1% SDS, 1% Igepal CA630, 2mM EDTA, 150mM NaCl, 50mM Tris-
HCl pH 7.4) supplemented with 7.5% protease inhibitor cocktail (PIC) (Roche 
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diagnostics, 11836170001) and incubated on ice for 40min. Cells were centrifuged at 
13,000xg for 5min and the supernatant was collected and stored at -20ºC. 
2.2.5.3 Bicinchoninic acid protein assay 
  Pierce BCA protein assay kit (Thermo scientific, 23225) was used to determine 
the protein concentration following the manufacturer’s protocol. A serial dilution of 
standards of bovine serum albumin (BSA) was prepared from a 2mg/ml BSA stock. 
In a 96-well flat bottom plate, the first well of standard was containing 1mg/ml of BSA 
diluted in NF-H2O. Standards were then serially diluted to 1:2 in NF-H2O.  
Samples were diluted to 1:50 in NF-H2O and 200µl was placed in the first well of 
each sample. Then the samples were serial diluted to 1:2 in the subsequent wells. Two 
wells were used as blanks containing NF-H2O. Samples and standards were done in 
duplicates. 100µl of BCA working solution was placed in each well. The plate was 
incubated at 37°C for 30min. The optical density was measured at a wavelength of 
562nm using the FLUOstar Omega plate reader (BMG labtech). The standard curve 
was plotted using Microsoft Excel and the concentration of protein was calculated 
accordingly. 
2.2.5.4 SDS-PAGE gel 
A 10% separating gel for sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE) was prepared by mixing 12.4ml distilled water (dH2O), 
9.6ml of 30% acrylamide (National Diagnostic, EC-890), 7.6ml separating gel buffer, 
448µl 10% ammonium persulfate (APS) and 20µl TEMED (Sigma-Aldrich, T9281) 
and loaded into 1.5mm thick SDS-PAGE plate. Once the gel was polymerised, a 
stacking gel was prepared by mixing 4ml dH2O, 1.2ml 30% acrylamide, 1.8ml 
stacking gel buffer, 112µl of 10% APS and 20µl TEMED. The stacking gel was 
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poured on the separating gel and a comb was placed to form the wells. Precast gels 
were used when available. 
Samples were diluted in NF-H2O in order to contain 10µg or 20µg of total protein. 
A 4x loading buffer was added and incubated at 95ºC for 5min. 20µl of samples were 
loaded onto the gel. The marker used was Precision Plus dual colour standards. The 
gel was electrophoresed in running buffer (prepared from 10x stock; 25mM Tris-base, 
250mM glycine, and 0.1% SDS in dH2O) at constant voltage 50V until the protein 
pass through the stacking gel then the voltage was increased to 120V. 
2.2.5.5 Immunoblotting 
The protein gel was blotted to a polyvinylidene difluoride (PVDF) transfer 
membrane (Millipore, IPVH00010), which was soaked in methanol before being 
placed on the gel. A transfer sandwich was electrophoresed in transfer buffer that was 
prepared from 1x transfer buffer with 15% methanol. The transfer was run at 250mA 
for one and half hours.  
The membrane was blocked with 5% milk in TBST (5% milk-TBST) buffer by 
incubating at RT for at least 1 hour. The membrane was probed with primary antibody 
(list of primary antibodies used in table 2.5) in 5% milk-TBST. The blocker solution 
was removed and the primary antibody was added and incubated overnight at 4°C. 
The primary antibody was removed and the membrane was washed 3 times with TBST 
for 10min each wash. The secondary antibody (HRP-goat anti-rabbit or HRP-goat 
anti-mouse) was diluted to 1:3000 in 5% milk-TBST and placed on the membrane, 
which was then incubated for 1 hour at RT. The secondary antibody was removed and 
the membrane was washed three times with TBST for 10min each wash.  
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The stain was developed by EZ-ECL Chemiluminescence detection kit for HRP 
(Biological industries, 20-500-120). The membrane was visualised by G.Box system 
(Syngen). 
The densities of the bands were determined using gene tools from Syngen or 
ImageJ1.45s software. The protein bands were selected using the selection tool in 
which a rectangle was drawn around each band. All rectangles were equal in size, 
narrowly bordering the sides of the widest band to avoid mixing between adjacent 
lanes but taller than the bands to allow the software to compare the dark bands against 
the white background. Appropriate exposures of blots were used and overexposure 
was avoided. The band densities are represented as arbitrary units. The density of 
proteins in the samples were normalised according to the density of α-tubulin or 
GAPDH. The expression level was calculated by comparing the normalised levels in 
the samples with that of the untransfected (UTF) sample. 
2.2.6 Virus Production 
2.2.6.1 LV production 
All steps were performed under sterile conditions in a class II safety cabinet. 
Protocol has been described previously in (Deglon et al., 2000) 
2.2.6.1.1 HEK293T cell culture for LV production 
 Cells were used at an early passage number (<30). Cells were counted on 
hemocytometer. Twenty 10cm tissue culture dishes were plated with 3x106 cells/dish 
and incubated overnight in the incubator. 
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2.2.6.1.2 Transfection of HEK293T cells with LV-insert plasmid and packaging 
plasmids 
For each petri dish, 1ml of DNA transfection mix containing 13µg pCMVΔR8.92, 
a packaging plasmid, 3µg pRSV-Rev, a plasmid encoding HIV-1 Rev protein which 
is essential for viral replication, 3.75µg pMD.G, plasmid encoding the vesicular 
stomatitis virus G envelope, 13µg of the LV-insert plasmid, 500µl 2x HBSS and 
topped up to 500µl with water and 0.25M CaCl2 prepared in water. The mix was 
incubated for 15min at RT and became translucent, then 1ml of the mixture was 
distributed to each dish and incubated for 6 hours in the incubator. Half of the medium 
was replaced with fresh full medium and incubated for 72hours in the incubator. 
2.2.6.1.3 LV purification and concentration 
All tools and centrifuge tubes and buckets were disinfected with 70% ethanol prior 
to use. All the media from the twenty dishes were pooled into one T75 flask and 
filtered with 0.45µm filters into a new flask to remove any cell debris. The virus-
containing supernatant was placed into 6 Ultra-clear centrifuge tubes (Beckman, 
344058) and then placed into the Beckman 115.6 buckets and balanced for 
centrifugation. They were centrifuged in the Beckman optima L-100K ultra centrifuge 
(Beckman, 393253) at 19,000rpm for 90min at 4ºC. The supernatant was decanted, 
and the viral pellet was suspended in 200µl of 1% BSA in PBS. All suspensions were 
pooled and mixed thoroughly. 50µl aliquots were stored at -80ºC. 
2.2.6.1.4 Determining the viral titre using HIV-1 p24 antigen ELISA kit 
The HIV-1 p24 antigen concentration was determined using the HIV-1 p24 
antigen ELISA kit (Zeptometrix, 0801111) following the manufacturer’s protocol. 
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Viral sample was lysed to 1:10 in lysis buffer provided in the kit. Six serial dilutions 
of each sample, including dilution factors of 100, 500, 2500, 12500, 62500 and 
312500, were prepared in 1% BSA in PBS. Five 1:2 serial dilutions of p24 antigen 
standards were prepared in the assay diluent starting with 125pg/ml. A wash buffer 
was prepared by diluting the provided 10Xwash buffer in autoclaved distilled water 
(dH2O). The provided HIV-1 p24 antibody coated microplate strips were washed with 
300µl washing buffer six times. 200µl of duplicate standards and samples were loaded 
into the wells, keeping 2 wells as blanks. The plate was sealed and incubated at 37°C 
overnight. Samples were removed and the wells were washed as above. 100µl of 
detector antibody was placed and the plate was sealed and incubated for 1hour at 37°C. 
The antibody was removed and excess antibody was washed as above. 100µl of 
Streptavidin-peroxidase was placed in each well and incubated at 37°C for 30min 
sealed. The plate was washed again as above. 100µl of substrate was placed in all wells 
and incubated at RT for 30min. 100µl of stop solution was added and the optical 
density was detected using the plate reader at a wavelength of 450nm. The standard 
curve was plotted using Excel (Microsoft office 2010). 
After calculating the concentrations of p24 antigen in the samples from the 
standard curve, the virus titre was calculated by multiplying the concentration of p24 
antigen by the dilution factor to determine its concentration in the stock sample:  
p24 antigen concentration in the viral stock (ng/ml)=
Optical density (OD)x dilution factor
1000
 
Since 1ng/ml of p24 equals to 1.2x104 transducible unit (TU)/ml, so the viral titre 
(TU/ml) = p24 antigen concentration x 1.2 x 104. 
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2.2.6.2 scAAV9 production 
A protocol has been mentioned previously in (Zolotukhin et al., 1999, Lock et al., 
2010) with slight modifications 
2.2.6.2.1 HEK293T cell culture for scAAV9 production 
For small scale production, a very confluent T175 flask was split as mentioned 
above into two 150mm dishes (VWR, 734-2322) the day prior to transfection. Cells 
would be 60-70% confluent on transfection day.  
For large scale production, fifteen very confluent 15cm dishes were split into thirty 
15cm dishes the day prior to transfection. The cell confluence would be around 80-
90% on the transfection day. Cells were grown in HEK293T full medium as mentioned 
above. For both productions the medium was replaced with serum free DMEM (SF-
DMEM) 2 hours prior transfection. 
 
2.2.6.2.2 Transfection of HEK293T cells with scAAV-insert plasmid 
Cells were transfected using Polyethylenimine (PEI) protocol in which the 
PEI:DNA ratio is 3:1 w/w. A stock of 1mg/ml PEI was prepared in sterile PBS. For 
every 15cm dish a mix of 156µl PEI, 26µg of pHelper, 13µg of pAAV2/9 and 13µg 
of the AAV-insert plasmids was prepared in 3ml SF-DMEM. The mix was allowed to 
stand at RT for 15min before being added to the cells. Cells were incubated for about 
5days at 37°C before harvesting. 
2.2.6.2.3 scAAV harvesting 
In small scale production some of the medium was collected in a falcon tube to 
detect virus content. In addition, cells were scraped and collected in a separate tube 
for virus content detection. The virus content in the cells was extracted by 
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homogenizing the cells in 500µl PBS and freeze-thawing the cells 3 times in a dry ice 
and water bath respectively. Cells were centrifuged at 10,000rpm for 5min to discard 
cell debris. The supernatant containing the virus was collected in fresh tube and kept 
at -80°C until validation. 
In large scale production the virus was collected from the medium, in which the 
medium was collected and Benzonase (Sigma, E1014-5KU) was added to the final 
concentration of 25units/ml. The medium was incubated at 37°C with occasional 
mixing for 2 hours. Cell debris was removed by centrifugation for 5min at 500xg and 
the supernatant was further filtered with Nalgene filter unit with 0.22µm pore 
membrane (Thermo scientific, 595-3320). 
2.2.6.2.4 scAAV concentration 
The virus was concentrated by centrifugation in Amicon Ultra-15 centrifugal filter 
Unit with Ultracel-100 membrane (Millipore, UFC910024) at 3800xg at 4°C until the 
required volume was achieved. 
2.2.6.2.5 scAAV purification by iodixanol density gradient 
Different concentrations of iodixanol solutions (stock is 60% w/v) (Sigma 
Aldrich, D1556-250ML) were prepared in PBS with 1mM MgCl2 and 2.5mM KCl 
(PBS-MK). The PBS-MK stock is prepared as 5x concentration. The solutions were 
prepared in 50ml falcon tube as follows: 
- 15% Iodixanol: 12.5ml iodixanol was diluted with 10ml 5xPBS-MK 10ml of 
5M NaCl and topped up to 50ml with sterile water. 
- 25% Iodixanol: 20.8ml of iodixanol was diluted with 10ml 5xPBS-MK with 
phenol red and topped up to 50ml with sterile water 
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- 40% Iodixanol: 33.3ml iodixanol was diluted with 10ml 5xPBS-MK and 
topped up to 50ml with sterile water. 
- 54% Iodixanol: 45ml iodixanol was topped up with sterile water and phenol 
red. 
In Quick-Seal centrifuge tube (Beckman Coulter, 344326) gradient solutions were 
added using 10mm 18G blunt-end needle (Hamilton, 7750-09) in the following order: 
first the concentrated virus solution was placed in the bottom of the tube. Then the 
15% iodixanol solution was added to the bottom of the tube. Next the 25% iodixanol 
solution was placed in the bottom. After that the 40% iodixanol was placed in the 
bottom of the tube. Finally, the 54% iodixanol solution was placed at the bottom of 
the tube and any space left was filled with PBS and bubbles were removed. The tube 
was sealed using a sealing device (Beckman Coulter, 358312). The tube was ultra-
centrifuged using 70Ti rotor (Beckman coulter) at 69,000rpm at 18°C for 1.5 hours 
without brake. The 40% fraction (clear solution) was collected in 500µl aliquots in 
1.5ml eppendorf tubes using a 19G syringe. 
2.2.6.2.6 Fraction analysis and SYPRO Ruby staining 
6µl of each fraction was diluted with water and Laemmli loading buffer (4x) and 
run on SDS-PAGE. SYPRO Ruby staining (molecular probes, S12000) was done 
following the manufacturers basic protocol, in which a fixative solution was prepared 
containing 50% methanol and 7% acetic acid diluted in dH2O, and a wash solution 
was prepared by mixing 10% methanol and 7% acetic acid in dH2O. The SDS-PAGE 
was placed in a 15cm dish and fixed twice in 60ml of fixative solution for 30min each 
with continuous agitation at RT. The gel was then stained with 60ml of SYPRO Ruby 
staining overnight with continuous agitation at RT protected from light. The gel was 
washed with 60ml of wash solution for 30min with continuous agitation. The gel was 
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transferred into a clean plate and rinsed with dH2O twice for five minutes each. The 
gel was viewed under UV light using GENi. Fractions showing the three AAV capsids 
purely without other bands were pooled and considered as a high quality virus prep, 
while the rest are considered as a low quality virus prep. 
2.2.6.2.7 scAAV desalting 
The pooled fractions were concentrated and desalted by centrifugation in Amicon 
Ultra-15 filters with PBS with 35mM NaCl at 3000xg at 4°C. Centrifugation was 
repeated and PBS-NaCl was added each time until the solution becomes clear. Viral 
solution was collected and aliquoted into eppendorf tubes and kept at -80°C. 
2.2.6.2.8 scAAV Titration by qPCR 
10µM stocks of each primer were prepared. Standards of linearized scAAV-HC 
plasmid were prepared by serial dilution in NF-H2O at 10
-1, 10-2, 10-3, 10-4, 10-5 and 
10-6. Serial dilution of scAAV-HC sample was done the same way. Two master mixes 
were made using two different sets of primers (table 2.3). 
For each sample a master mix was as follows: 
 1µl of 10µM forward primer 
 1µl of 10µM reverse primer 
 5µl of SYBR green (x2) master mix (Agilent Technologies, 600828) 
 1µl NF-H2O 
Master Mix was added to 2µl of samples or standards on PCR plate. Water was 
used as blank. Samples and standards were done in duplicates. The plate was sealed 
and qPCR was run for 35 cycles of 95°C for 5min, 95°C for 10sec and 60°C for 30 
sec. Data was analyzed on Biorad CFX manager software version 3.1 and titer was 
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calculated by multiplying the readings by the dilution factor and by 1000 to get 
copies/ml. 
 
Table 2.3: Primer sets used for scAAV titration 
Primer set Forward primer Reverse primer 
Set 1 
(CMV) 
GGTAAATGGCCCGCCTGGCA GCGTCAATGGGGCGGAGTTGT 
Set 2 (HC-
ARFIP2) 
ATGCTCAGCCAGAAGTCC GCAGCCTCATACTGTTTCAC 
2.2.7 Validation of viral products 
2.2.7.1 Transduction of HEK293T cells 
HEK239T cells were cultured on a 6-well plate at a density of 100,000cells/well 
in 2ml full medium and incubated overnight at 37ºC.  
For LV transduction, the required volume of virus was calculated using the 
following equation: 
volume from virus stock (ml)=
multiplicity of infection (MOI)x no. of cells
viral titre
 
The viral vectors were thawed on ice. One ml of the medium was removed from 
the well and the calculated volume of viral suspension was added to each well. The 
cells were incubated in the incubator for 6 hours, then fed with 1ml of full medium 
and incubated for another 72 hours. 
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2.2.8 In vitro experiments 
2.2.8.1 Primary motor neuron culture 
Primary motor neurons of mouse embryos were extracted using the 
immunopanning technique (Ramon-Cueto and Nieto-Sampedro, 1992, Wiese et al., 
2010, Graber and Harris, 2013). Technical support was provided by Dr.Ke Ning.  
10mm coverslips were placed in 35mm dishes with 4x10mm rings (Greiner bio-
one, 627170) and were coated overnight with 5% poly-DL-ornithine hydrobromide 
(PORN) (Sigma, p-8638) in 0.15M Borate buffered saline pH 8.2 (Fluka analytical, 
08059) at 4ºC. The PORN was removed and coverslips were washed with HBSS then 
the coverslips were coated with 1.5µg/ml Laminin (Invitrogen, 23017-015) that was 
prepared by diluting 0.75mg/ml Laminin stock in 50mM Tris pH 7.4, in HBSS. 
Pregnant mice were sacrificed by cervical dislocation and the embryos were 
collected at E13. The embryo tails were used for genotyping and the spinal cords were 
extracted and placed in the dissection buffer (1:1000 β-ME (Invitrogen, 313500) in 
HBSS). The cells were dissociated with 0.1% trypsin (Worthington, TLR3-3707) by 
incubating at 37ºC for 15min. Trypsin was deactivated by the trypsin inhibitor (Sigma, 
T-6522). Motor neurons were then selected by placing the cell suspension in a 12-well 
plate pre-coated with 1:5000 anti-p75 NGF receptor antibodies (Abcam, ab8877) in 
10mM Tris buffer at pH 9.5. Unattached cells were washed off with washing media 
(NB medium with 0.2µM β-ME), and the motor neurons were detached by 
depolarising buffer (30mM KCl (Sigma, P9333) and 0.8% NaCl (Sigma-Aldrich, 
S7653) and plated on the pre-coated coverslips at concentration of 2000-
5000cells/coverslip in low volume of primary motor neuron full medium. Cells were 
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incubated in the incubator for at least 1 hour to allow the adhesion of cells prior to 
addition of more medium. 
2.2.8.1.1 SOD1G93A transgenic mice breeding and genotyping  
SOD1G93A mice are common models used for ALS research, expressing the 
mutation of glycine to alanine at position 93 of human SOD1 (Gurney, 1997). The 
mice used in this study were generated by backcrossing C57BL/6J TG 
(SOD1G93A)1Gur congenic mice (Jackson Laboratories) with C57BL/6 mice 
(Charles River Laboratories) for more than 10 generations. To obtain SOD1G93A-TG 
and NTG littermates embryos, SOD1G93A male mice were mated with C57BL/6 
female mice. The phenotypic characteristics of these mice have been described 
elsewhere (Mead et al., 2011). Mice were bred and maintained by Dr. Ellen Bennett 
and Ian Coldicott.  
To genotype the mice, DNA extraction was done using QuickExtract DNA 
Extraction Solution (Epicentre Biotechnologies, QE09050) following the 
manufacturer’s protocol in which DNA extracts from ear clip or tail clip were 
extracted in 50µl or 15µl of the QuickEXtract solution, respectively, and incubated at 
65°C for 1hour then at 98°C for 5 min.  
A PCR mix was prepared by mixing 10µl of FIREPol 5x Master Mix, 0.1µl of 
50µM stock of each primer (human SOD1 (hSOD1) forward and reverse primers) and 
mouse IL-2 (mIL-2) primers as controls (Table 2.4), 1µl of the DNA extract and the 
volume was topped up to 25µl with NF-H2O. A known positive transgenic (TG) 
SOD1G93A DNA was used as a positive control and a known non-transgenic (NTG) 
DNA and NF-H2O were used as negative controls. The PCR was run as mentioned 
above. PCR products were analysed using a 2% agarose gel. 
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Table 2.4: List of primers used in SOD1G93A genotyping 
hSOD1 forward 
primer  
CATCAGCCCTAATCCATCTGA 
hSOD1 reverse primer CGCGACTAACAATCAAAGTGA 
mIL-2 forward primer CTAGGCCACAGAATTGAAAGATCT 
mIL-2 reverse primer GTAGGTGGAAATTCTAGCATCATCC 
 
2.2.8.1.2 Primary motor neurons transfection with plasmid DNA 
Cell transfection was performed under sterile conditions in a class II cabinet. A 
transfection mix was made of ~2ng/µl of DNA in serum free Opti-Minimal Essential 
Medium (Opti-MEM) (GIBCO, 31985-070) and Fugene transfection reagent 
(Promega, 31812701). Briefly, for each 35mm dish containing 2ml full medium a 
transfection reagent mix was prepared by mixing 3µl Fugene and 100µl Opti-MEM 
and left standing at RT for 10-15min, then 1µl of the 0.2µg/µl DNA was added. Each 
35mm dish was treated with 100µl transfection medium, leading to a final 
concentration of 0.1ng DNA/µl. 
Cells were incubated at 37ºC with 5% CO2 overnight and 90% of the media was 
replaced with fresh full media on the following day, then cells were incubated at 37ºC 
for a further 3 days. Cells were checked under microscope every day. Then the cells 
were either treated with 10mM hydrogen peroxide (H2O2) or washed with 1ml 
Dulbecco`s Phosphate Buffered Saline (DPBS) without Ca, Mg (Lonza, 17-512F) and 
fixed, as detailed below. 
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2.2.8.1.3 Primary motor neurons transduction with LV 
Cell transduction was performed under sterile conditions in class II cabinet 
specified for LV usage. Cells were transduced with MOI100 at low medium for 2 
hours at 37°C. Primary motor neurons full medium was topped up and the cells were 
incubated for 5days at 37°C. Cells were checked daily and medium was added when 
necessary. 
2.2.8.1.4 Propidium Iodide (PI) Exclusion Assay 
A stock of 2M H2O2 was prepared by diluting 2.3ml of 30% (w/w) H2O2 (MW= 
340.1g/mol) (PERDROGEN, 31642) in 7.7ml distilled water (dH2O). Each 35mm dish 
was treated with 10µl of 2M H2O2 leading to a final concentration of 0.01M. The cells 
were incubated at 37ºC for 50min. Then 1ml of the medium was removed, and the 
cells were treated with 5µl PI and incubated at 37ºC for 10min. The medium was 
removed, and the cells were washed once with 1ml DPBS and fixed. 
2.2.8.1.5 Cell fixation 
The cells were fixed with 4% paraformaldehyde (PFA) (Sigma-Aldrich, P6148) 
by placing 1ml PFA in each 35mm dish and incubated at RT for 15min. The PFA was 
removed and 1.5-2ml autoclaved phosphate buffered saline (PBS) (0.01 M phosphate 
buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride, pH 7.4)(Sigma, 
P4417) was placed and the plate was sealed with parafilm and kept at 4ºC until staining. 
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2.2.8.1.6 Statistical analysis 
PI positive and PI negative cells were counted and the sum of them was considered 
as 100% cell number. The statistical analysis was done using GraphPad Prism 6 
version 6.04 software using One-way ANOVA. 
2.2.9 Immunofluorescence (IF) 
2.2.9.1 Immunocytochemistry 
A stock of 5% Triton X-100-PBS was prepared by diluting 5 ml of Triton X-100 
(Sigma-Aldrich, X-100) in 95 ml of PBS and stored at 4ºC. A working 
permeabilization buffer of 0.25% Triton-PBS was prepared by diluting 2.5ml of the 
5% Triton-PBS stock in 47.5ml PBS. 
The PBS was removed from the plates and 50µl of 0.25% Triton-PBS was placed 
on each ring of the 35mm dish and incubated for 20min at RT to allow penetration of 
antibodies. Then nonspecific antigen recognition was blocked with 50µl of blocker, 
which is made of 10% Goat serum (GS) (Sigma, G-9023) in 0.25% Triton-PBS, for 
each ring and incubated for 30min at RT.  
 The primary antibody was diluted in 0.25% Triton-PBS following the 
concentrations specified in Table 2.5. 30µl of the primary antibody mix was placed on 
each ring and incubated overnight at 4ºC.  
The primary antibody was removed and the cells were washed 3 times for 5min 
each with 1ml PBS. A secondary antibody mix diluted in 0.25% Triton-PBS with 10% 
GS (Table 2.6). The nucleus was stained with Hoechst stain (Sigma, 861405), diluted 
to 1:1000 in the same secondary antibody mix. 30µl of the secondary antibody mix 
was placed on each ring. The plate was covered with foil and incubated at RT for 2 
hours. 
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The antibody was removed and the cells were washed 3 times for 5min each with 
1ml PBS. The coverslips were mounted on glass slides using fluorescent mounting 
medium (Dako, S3023). 
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Table 2.5: List of primary antibodies used in immunostaining and western blot 
Antibody Specificity  Dilution 
factor 
IF/WB 
Supplier 
Mouse anti-α-
tubulin 
Detect the ~60kDa tubulin 
.Reacts with chicken, 
gerbil, human, mouse, rat 
-/1:5000 Calbiochem, CP06 
Mouse anti-
Arfaptin2 
Reacts with full length 
human Arfaptin2 
1:100/1:1000 Sigma, 
WH0023647M1 
Rabbit anti-
SOD1 
Reacts with mouse, rat and 
human full length SOD1 
1:100/1:1000 Santa Cruz, sc-
11407 
Rabbit anti-
TDP43 
Detects mouse, rat and 
human TDP43 
1:100/1:1000 Cell Signaling 
technology, 3448S 
Rabbit anti-
Arfaptin2 
Reacts with 15 amino acid 
peptides from the C-
terminal residues of 
mouse, rat and human 
Arfaptin2.  
1:100/1:1000 Abcam, ab85106 
Mouse anti-
TDP43 
Reacts with full length 
protein human TDP43 
1:200/1:1000 Abcam, ab57105 
Mouse anti-
hemagglutinin 
(HA) 
Detects YPYDVPDYA 
(98-106) of HA 
1:200/1:1000 Sigma Aldrich, 
H9658 
Mouse anti-
SQSTM1/p62 
Reacts with mouse, human 
and rat p62 
1:100/1:1000 Millipore, MABC32 
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Rabbit anti- 
Calcitonin 
Gene Related 
Peptide 
(CGRP) 
Detects rat and human 
CGRP 
1:100/1:1000 Sigma, C8198 
Mouse anti-
beta III 
Tubulin 
(TUJ1) 
Reacts with human beta III 
tubulin 
1:200 Neuromics, 
MO15013 
Rabbit anti-
LC3 
Reacts with human, mouse, 
rat, bacteria, bovine, 
porcine, hamster and 
zebrafish 
-/1:1000 Novus 
biotechnology, 
NB100-2220 
Rabbit anti-
Atg13 
Reacts with human, mouse, 
rabbit and monkey. 
-/1:1000 Cell Signaling 
technology, 6940 
Rabbit anti-
ULK1 
Reacts with human, mouse, 
rabbit and monkey. 
-/1:1000 Cell Signaling 
technology, 8054 
Rabbit anti-
phospho-Akt 
(Ser473) 
Reacts with human, mouse, 
rabbit and monkey 
1:200/1:1000 Cell Signaling 
technology, 4060 
Rabbit anti- 
Phospho-4E-
BP1 
(Thr37/46) 
Reacts with human, mouse, 
rabbit and monkey. 
-/1:1000 Cell Signaling 
technology, 9459 
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Rabbit anti-
hSOD1 
Reacts specifically with 
human SOD1 protein 
1:200 Millipore, AB5480 
Rabbit anti-
PTEN 
Recognizes human PTEN 
when phosphorylated at 
Ser385 
1:200/ 1:1000 Life Sciences, 
P9182-02R 
Rabbit anti-
Akt 
Detects Akt1 and Akt3 
from human, mouse and 
rabbit 
-/1:1000 Cell signaling, 2966 
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Table 2.6: List of secondary antibodies used in immunostaining and western blot 
Antibody Properties Dilution factor Supplier 
HRP- goat anti-
mouse IgG (H + 
L)  
Reacts with whole 
molecule mouse 
IgG 
1:3000 Bio-rad, 170-6516 
HRP-goat anti-
rabbit IgG (H + 
L) 
Reacts with whole 
molecule rabbit IgG 
1:3000 Millipore, 12-348 
Fluorescein 
(FITC)-
AffiniPure goat 
anti-rabbit IgG 
(H+L) 
Reacts with whole 
molecule rabbit IgG 
1:200 Jackson, 111-095-003 
Alexa Fluor 350 
goat anti-mouse 
IgG (H+L) 
Goat IgG labeled 
with blue-
fluorescent Alexa 
Fluor 350 dye and 
reacts with IgG 
heavy chains and all 
classes of 
immunoglobulin 
light chains from 
mouse 
1:200 Invitrogen, A-11045 
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FITC-AffiniPure 
Donkey anti-
mouse IgG (H+L) 
Reacts with whole 
molecule mouse 
IgG 
1:200 Jackson, 715-095-151 
Alexa Fluor 488 
goat anti-mouse 
IgG (H+L) 
Goat IgG labeled 
with blue-
fluorescent Alexa 
Fluor 488 dye and 
reacts with IgG 
heavy chains and all 
classes of 
immunoglobulin 
light chains from 
mouse 
1:200 Invitrogen, A11017 
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CHAPTER 3: Using Lentivirus-based vectors to investigate 
the effect of Arfaptin2, HC-ARFIP2 and TDP43 over-
expression on primary motor neuron survival  
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3.1 Introduction 
Nucleic acid gene transfer (transfection) to neuronal cells in vitro presents a great 
challenge in research. This is due to the high sensitivity of the neurons to physical 
challenges and inability to proliferate. Different transfection methods have been 
developed and improved in order to tackle those issues. These methods include 
chemical (such as lipofection and calcium phosphate/DNA coprecipitation), physical 
(such as electroporation and microinjection) transfection methods or viral-based (such 
as retrovirus, adeno-associated virus and lentivirus) transduction. Each method has its 
strengths and limitations. However, none of them seems to be effective to be used as 
a standard in all experiments. Different neuronal models and expected outcomes of 
experiments might require different transfection method. Different transfection 
methods for neuronal cells have been reviewed previously (Karra and Dahm, 2010). 
The transfection method that was tested in this project was the liposomal 
transfection method in which FuGene reagent was used. We wanted to overexpress 
FL-ARFIP2 or HC-ARFIP2 in primary motor neurons and study their effects on 
primary motor neuron survival. This transfection method led to widespread cell death. 
Several attempts were tried to reduce cell death caused by stress while handling. 
Although approximately 2000 cells/coverslip were plated, by the end of transfection 
incubation period only very few, if any, cells  survived. This was observed in mock 
transfected as well as FL-ARFIP2, HC-ARFIP2 and TDP43 transfected samples. 
Therefore, survival analysis was not conducted. It was observed that this transfection 
method was unsuitable for primary motor neurons and therefore, we sought to move 
onto a different gene transfer method using a viral vector (transduction). 
One of the major advantages of using viral based vectors as gene delivery agents 
is their low toxicity as they are naturally capable of entering the cells without causing 
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physical stress, which overcomes the problem of transfection. One of the most 
efficient viral vectors is the LV. 
LV is a genus of the Retroviridae family. It consists of a double stranded RNA. 
LV showed the ability to integrate into the genome of non-dividing cells making it 
perfect for transducing primary motor neurons (Naldini et al., 1996, Gerolami et al., 
2000). In addition, it provides sustained long-term gene transfer with high efficiency 
and low toxicity in cells of the CNS (Blomer et al., 1997). In the recombinant LV, the 
genes required for their replication have been removed; though handling them still 
requires biosafety level 2.  
LV has been used in gene therapy studies in neuronal diseases, including PD, in 
which some LV therapeutics went into clinical trials and were proved to be safe (Palfi 
et al., 2014). LV vectors were used in an in vitro ALS model to overexpress 
antioxidant response element genes (ARE) in motor neuron-like cell line (NSC34). 
The overexpression of those genes was able to decrease the damage caused by 
oxidative stress and increase survival in NSC34 cells (Nanou et al., 2013). 
Furthermore, transduction of primary motor neurons using LV-based vectors have 
been shown to be more efficient and less toxic compared to conventional transfection 
methods (Bender et al., 2007). 
In this project a human immunodeficiency virus (HIV)-based third generation LV 
vector that is replication-deficient and self-inactivating (Sin) has been used. The gene 
of interest was under the control of the phosphoglycerate kinase (PGK) promoter, 
which promotes sustained long-term expression (Zufferey et al., 1998, Gerolami et al., 
2000). In addition, the LV vector expresses the central polypurine tract element (cPPT) 
which enhances the import of the provirus into the nucleus and subsequently induces 
Chapter 3: Survival Study 
80 
 
 
genetic integration of the desired gene with the cell’s genome, especially in non-
dividing cells (Van Maele et al., 2003).  
The human influenza hemagglutinin (HA) tag was used as an epitope tag to 
facilitate the detection of the overexpressed proteins and identify them from the 
endogenous protein. It is a well-characterised-immunoreactive tag that does not affect 
the function and expression of the desired gene (Lo et al., 2003). It is short, so it does 
not affect the packaging capacity of the virus and it is not toxic as GFP (Baens et al., 
2006). This tag has been used to facilitate the detection of the desired proteins on 
western blot and immunofluorescence staining.  
3.2 Aim 
The aim of this chapter is to evaluate the pro-survival potential of HC-ARFIP2 in 
primary motor neurons to support what has been found previously by our research 
group in NSC34 model (Kong, 2011). In order to achieve this aim we needed to 
produce LV-based vectors to overcome the low transfection efficiency and high cell 
toxicity in primary motor neurons, which have been observed when using liposomal 
transfection method, and subsequently investigate the effect of FL-ARFIP2, HC-
ARFIP2 or TDP43 overexpression on primary motor neuron survival. 
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3.3 Results 
3.3.1 Construction of LV-ARFIP2, LV-HC-ARFIP2 and LV-TDP43 plasmid 
vectors 
In order to produce a viral vector expressing a gene of interest, the desired gene 
had to be subcloned into the viral genome backbone that will carry the gene inside the 
virus particle and mediate its expression in the cells. 
3.3.1.1 FL-ARFIP2, HC-ARFIP2 and WT-TDP43 amplified by PCR 
Subcloning is the procedure of transferring one gene of interest from one vector 
into another vector. In this case, the FL-ARFIP2 and HC-ARFIP2 were transferred 
from a pcDNA3 plasmid containing Arfaptin2 into the Sin-PGK-cPPT vector 
(hereafter called LV-backbone). All genes that were introduced into the viral vector 
genome were amplified by PCR. The FL-ARFIP2 and HC-ARFIP2 DNAs were 
amplified from pcDNA3 plasmid encoding Arfaptin2. FL-ARFIP2 was designed to 
contain BglII restriction site at the 5’end. The HC-ARFIP2 primer was designed to 
contain BamHI restriction site at the 5’end. Both primers were designed to contain an 
HA-tag and XhoI site at the 3’end. The PCR products were run on a 1% agarose gel 
and the desired bands were purified by DNA-gel extraction kit. The expected size for 
FL-ARFIP2 is 1kbp and the size of HC-ARFIP2 is ~0.5kbp (Figure 3.1 a). 
The WT-TDP43 was amplified from pDONR221 plasmid that expresses the WT-
TDP43. The amplified product was visualised on 1% agarose gel and corresponded to 
the predicted size at 1.25kbp (Figure 3.1 b). It was extracted and purified as above. 
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Figure 3.1: PCR products for LV subcloning. a) PCR products for HC-ARFIP2 
and FL-ARFIP2 were run on 1% agarose gel. Known HC-ARFIP2 and FL-ARFIP2 
samples were used as controls. The purified HC-ARFIP2 DNA is at ~0.5kbp and 
the FL-ARFIP2 DNA is at 1kbp. b) Amplified PCR product of TDP43 at expected 
size of 1.25kbp 
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3.3.1.2 PCR products and LV-backbone digestion 
The PCR products of FL-ARFIP2 and HC-ARFIP2 were digested with BglII or 
BamHI, respectively, and XhoI then purified by QIAquick gel extraction kit (Figure 
3.1 a). Accordingly, the Sin-PGK-cPPT-GDNF plasmid was digested with the same 
restriction enzymes (BamHI and XhoI) to remove the GDNF cassette and to be 
replaced with the desired inserts (Figure 3.2). LV-backbone at 10kbp was gel extracted 
and purified by gel extraction kit. 
 
 
 
 
 
 
 
Figure 3.2: LV-GDNF digestion. The LV-GDNF plasmid was digested by BamHI and 
XhoI. The LV-backbone size is ~10kbp. It was extracted from the gel, purified and 
measured with Nanodrop. 
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3.3.1.3 Restriction sites added to the TDP43 construct for subcloning 
TDP43 PCR product containing BamHI restriction site on the 5’end and XhoI 
restriction site on the 3’end was subcloned into TOPO vector using the TOPO TA 
cloning kit and then transformed into TOP10 E.coli. Transformed bacteria were 
cultured and plated. A Few colonies were picked and cultured to be tested for 
successful addition of restriction sites to the cDNA. Plasmid minipreps were extracted 
from the bacterial cultures and were analysed by restriction digest analysis. Plasmid 
DNAs were digested by BamHI and XhoI. The digested products were run on 1% 
agarose gels. The upper band at ~4kbp (Figure 3.3) represents the TOPO vector, while 
the lower band ~1.25kbp represents the TDP43. Figure 3.3 shows the successful 
insertion of TDP43 into TOPO vector that was successfully digested at the desired 
sites. Further confirmation was done by sequencing.  
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Figure 3.3: TDP43 successful ligation with TOPO vector. Successful expression 
and digestion of TDP43 with BamHI and XhoI in TOPO vector. TOPO vector 
backbone ~4kbp while the TDP43 cDNA runs at ~1.25kbp 
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3.3.1.4 Genes of interest subcloned into the LV plasmid 
The target inserts (FL-ARFIP2 or HC-ARFIP2 from figure 3.1a and TDP43 from 
Figure 3.3) were ligated into the LV-backbone between BamHI and XhoI restriction 
sites. The ligation mixtures were transformed into XL10-gold E.coli. Several colonies 
from the transformed bacterial cultures were picked and plasmids were extracted using 
a plasmid miniprep kit. Plasmid-preps expressing successful ligations were analysed 
using BamHI and XhoI restriction enzymes and visualised on an agarose gel. Figures 
3.4, 3.5 and 4.6 show representative plasmid-maps of LV vectors with the inserted FL-
ARFIP2, HC-ARFIP2 or TDP43 transgene, respectively. They also show the 
successful insertion of the genes into the LV as validated by digestion showing LV-
backbone at 10kbp, FL-ARFIP2 at 1kbp, HC-ARFIP2 at 0.5kbp and TDP43 at 
1.25kbp. Figure 3.6 shows successful insertion of TDP43 into the LV-vector in four 
colonies (2-5) while colony one was excluded as it was not digested as desired. Correct 
DNA insertion was further validated by DNA sequencing to confirm that no 
spontaneous mutations had occurred during the cloning process (see appendices). 
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Figure 3.4: Insertion of FL-ARFIP2 into the Lentiviral vector. a) Plasmid map 
represents the LV-ARFIP2 sequence with unique restriction sites. b) FL-ARFIP2 
was ligated into the LV-backbone then plasmid extracts were digested with BamHI 
and XhoI. The gel image shows successful ligation and digestion at the right sizes 
in all picked colonies (LV-backbone at ~10kbp and FL-ARFIP2 at 1kbp) 
 
Chapter 3: Survival Study 
88 
 
 
 
 
 
 
 
Figure 3.5: Insertion of HC-ARFIP2 into the Lentiviral vector. a) Plasmid map 
represents the LV-HC sequence with unique restriction sites. b) HC-ARFIP2 was 
ligated to the LV-backbone and transformed into XL10-gold cells. Plasmid extracts 
from 5 colonies were digested with BamHI and XhoI. The picture shows successful 
ligation and digestion at the expected sizes in all picked colonies (LV-backbone at 
~10kbp and HC-ARFIP2 at 0.5kbp) 
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Figure 3.6: Insertion of TDP43 into the Lentiviral vector. a) Plasmid map 
represents the LV-TDP43 sequence with unique restriction sites. b) TDP43 was 
ligated to the LV-backbone and transformed into XL10-gold cells. Plasmid extracts 
from 5 colonies were digested with BamHI and XhoI. The sample number 1 shows 
incorrect digestion of the plasmid, the rest of the samples showing successful ligation 
and digestion at the expected sizes (LV-backbone at ~10kbp and TDP43 at ~1.25kbp) 
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3.3.2 LV-based vectors efficiency testing 
3.3.2.1 LV-based plasmids efficiently overexpress the proteins of interest 
HEK293T cells were transfected with LV-ARFIP2, LV-HC or LV-TDP43 
plasmids in order to confirm the efficiency of the plasmids prior to the viral 
production. Calcium phosphate or PEI transfection methods were used. The proteins 
were extracted 3 days post transfection, and the concentrations were determined by 
BCA protein assay. Expression levels of FL-ARFIP2, HC-ARFIP2 and TDP43 were 
determined by Western blot assay, using α–tubulin as a loading control. The successful 
expression of FL-ARFIP2 or HC-ARFIP2 was evaluated by the presence of bands at 
38kDa and 19kDa, respectively (Figure 3.7), in the transfected samples compared to 
the untransfected controls. Figure 3.7 shows successful expression of FL-ARFIP2 and 
HC-ARFIP2 as they were detected by anti-HAtag antibody.  
The TDP43 was detected using rabbit anti-TDP43 antibody as a primary antibody 
and then stained with HRP-conjugated goat anti-rabbit antibody as a secondary 
antibody. The successful overexpression of TDP43 was evaluated by comparison of 
band densities between the transfected and untransfected cells. Comparing the band 
densities of the LV-TDP43 transfected samples with the untransfected control, the 
result shows successful overexpression of TDP43 to over 13 fold (Figure 3.8).  
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Figure 3.7: Validation of the LV-based plasmids expressing FL-ARFIP2 or 
HC-ARFIP2. HEK293T cells were transfected with the LV-based plasmids 
expressing FL-ARFIP2 or HC-ARFIP2. FL-ARFIP2 and HC-ARFIP2 expression 
was detected on a western blot by mouse anti-HA antibody. FL-ARFIP2 is detected 
at ~38kDa while the HC-ARFIP2 is detected around 20kDa. α-tubulin was used as 
a loading control  
Figure 3.8: Validation of the LV-based plasmids expressing TDP43. HEK293T 
cells were transfected with the LV-based plasmids expressing TDP43. The TDP43 
was detected by rabbit anti-TDP43 antibody at 43kDa. α-tubulin was used as a 
loading control 
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4.3.2.2 LV-based viral vectors efficiently overexpress the proteins of interest 
Once plasmids were validated, LV-ARFIP2, LV-HC and LV-TDP43 viruses were 
produced using the 4 plasmid transfection method, in which cells were transfected 
with two packaging plasmids, one envelope plasmid and a lentivirus vector plasmid 
expressing our gene of interest (see Section 2.2.6.1 for full details about the plasmids). 
Viruses were collected from the culture medium, filtered from cellular debris then 
concentrated using ultracentrifugation. The viral titres were determined using the p24 
antigen ELISA kit. Viral titres ranged between 105-108 transducable units (TU/ml) 
from which only viruses with high titres (107-108 TU/ml) were used in transduction 
assays. To validate the efficiency of the produced viruses, HEK293T cells were 
transduced with different multiplicity of infection (MOI) of LV-ARFIP2, LV-HC or 
LV-TDP43. Cells were harvested 5 days post transduction and the protein was 
extracted and measured as above. Transgene expression was detected by western 
blotting and measured by densitometry when possible.  
Every validation was repeated three times before proceeding with the in vitro 
experiments. Figures 3.9 and 3.10 show that the viruses produced were efficiently 
overexpressing the desired proteins with both low and high MOIs. They also show that 
there is a correlation between the MOIs used and the level of overexpression. Figure 
3.10 shows that even with low MOI there was approximately 5 fold overexpression of 
TDP43; while analysis of MOI10 revealed a significant increase of an average of 15 
fold of TDP43 (n=3, p<0.05) (Figure 3.10b). This step was necessary to confirm the 
efficiency of the viruses prior to motor neuron transduction. It is noticeable that HC-
ARFIP2 expression is relatively much lower than FL-ARFIP2 and TDP43 
overexpression. Therefore, higher MOIs of LV-HC were used in subsequent 
experiments. 
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Figure 3.9: LV-ARFIP2 and LV-HC efficiently express FL-ARFIP2 and HC-
ARFIP2 in HEK293T cells, respectively. HEK293T cells were transduced with 
LV-ARFIP2 or LV-HC virus. Protein was extracted 5 days post transduction. 
Western blot shows the FL-ARFIP2 (a) and HC-ARFIP2 (b) expression detected 
by anti-HA antibody. There is a correlation between the MOI level and the 
expression level of FL- and HC-ARFIP2. c) Cells were fixed 5 days post 
transduction, Immunofluorescence shows FL- and HC-ARFIP2 expression 
detected using anti-HA antibody (green) while endogenous ARFIP2 was detected 
by anti-ARFIP2 antibody (red). Scale bar = 20µm 
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Figure 3.10: LV-TDP43 efficiently overexpresses TDP43 in HEK293T cells. a) 
HEK293T cells were transduced with different MOIs of LV-TDP43 virus. A 
representative western blot shows TDP-43 detected using anti-TDP43 antibody. b) 
The overexpression level (Mean ± SEM) was determined by densitometry of western 
blot. The TDP-43 expression level was compared between transduced and 
untransduced samples after normalisation with α-tubulin. Statistical analysis was 
done using one-way ANOVA test. n=3. * ; p <0.05 
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3.3.2.3 LV-based viral vectors efficiently express proteins of interest in motor 
neurons 
As a further validation of the LV-based vector efficiency, primary motor neurons 
were transduced with the viruses and harvested 5 days post transduction for protein 
analysis. Western blots were probed as above. Figures 3.11, 3.12 and 3.13 show that 
FL-ARFIP2, HC-ARFIP2 and TDP43, respectively, were successfully expressed at 
high levels compared to untransduced samples. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11: LV-ARFIP2 expresses FL-ARFIP2 in motor neurons. Primary 
motor neurons were transduced with two different MOI levels of LV-ARFIP2 virus. 
FL-ARFIP2 detected by mouse anti-HA-tag antibody. There is abundant expression 
of FL-ARFIP2 with both MOIs. 
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Figure 3.12: LV-TDP43 overexpresses TDP43 in motor neurons. Primary motor 
neurons were transduced with two different MOI levels of LV-TDP43 virus. 
TDP43 was detected by rabbit anti-TDP43 antibody, which also detects 
endogenous TDP43.  
Figure 3.13: LV-HC expresses HC-ARFIP2 in motor neurons. Primary motor 
neurons were transduced with two different MOI levels of LV-HC virus. HC-
ARFIP2 detected by mouse anti-HA-tag antibody.  
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3.3.3 Increased primary motor neuron survival with HC-ARFIP2 expression 
The effect of HC-ARFIP2 over expression on motor neuron survival was 
determined by propidium iodide (PI) exclusion experiment. The principle of the assay 
is that PI intercalates between DNA bases and it is a fluorescent molecule that when 
excited shows red fluorescence. However, it is membrane impermeable. Therefore, 
viable cells which have intact membrane will be PI negative while dead cells will be 
PI permeable and therefore will show red nuclei. In other word, cell death was detected 
by positive PI staining. On the other hand, Hoechst 33342 is a membrane permeable 
intercalating agent and produces blue fluorescence when excited. Therefore, Hoechst 
will stain the nuclei of both live and dead cells. 
Primary motor neurons from NTG and SOD1G93A TG mouse embryos were 
extracted and cultured, using immunopanning technique. Cells were transduced with 
LV-ARFIP2, LV-HC or LV-TDP43 viruses. Five days post transduction, half the 
culture plates were induced with 10mM H2O2 for 50 min to investigate the effect of 
oxidative stress. Afterwards, all cell cultures were treated with PI for 10 min, and then 
washed and fixed directly.  
Cells expressing FL-ARFIP2 and HC-ARFIP2 were detected by 
immunofluorescent staining with anti HA-tag antibody, while TDP43 overexpression 
was detected by anti TDP43 antibody. Untransduced control cells were labelled with 
TUJ1 antibody, which recognises beta-III-tubluin. The nuclei were stained with 
Hoechst 33342.  
Figure 3.14 is an example taken at low magnification for a successful motor 
neuron culture immunostained with HA antibody for FL-ARFIP2 detection. However, 
the PI staining was only obvious at higher magnification. Figure 3.15 shows an 
example of live and dead cells, which are PI positive or PI negative, respectively, from 
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a control slide taken at 63x magnification power. In addition, Hoechst 33342 staining 
was used as a confirmation to differentiate the dead cells as their nuclei show 
chromatin condensation. This has been widely used for detection of apoptotic cells 
(Antonelli et al., 2008, Kameswaran and Ramanibai, 2009). Figure 3.15 shows that PI 
positive dead cells also have DNA condensation with the Hoechst 33342 staining 
compared to the nuclei of cells that are PI negative. 
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 PI positive and negative cells were counted blindly from four fields, in which 
each shows at least one motor neuron, of each coverslip. An average of 90 cells was 
counted per sample. The percentage of cell survival was determined from the total 
number of cells counted from each sample. The experiment was repeated on 3 
independent experimental repeats. Each repeat consisted of at least two TG and NTG 
embryos. Statistical analysis was performed on Graphpad Prism and the statistical 
significance was calculated using one-way ANOVA test. 
The results show that HC-ARFIP2 expression significantly increases motor 
neuron survival of the TG embryos compared to the overexpression of TDP43, FL-
ARFIP2 and the untransduced control by around 20% (n=3; p<0.05). This is true in 
both non-stressed and H2O2 stressed cells (Figures 3.16). Comparing 3.16 a and 3.16 
b, there is approximately 10% more cell death in the samples stressed with H2O2, 
which is expected. 
NTG motor neurons also show similar results with significant difference between 
HC-ARFIP2 expression and other treatments and controls in non-stressed motor 
neurons (n=3; p<0.05), while H2O2 stressed motor neurons showed only significant 
difference between HC-ARFIP2 overexpressing cells and other samples excluding 
control (n=3; p<0.05) (Figure 3.17).  
 
 
 
 
 
 
 
Chapter 3: Survival Study 
102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16: SOD1G93A transgenic motor neuron survival. Primary motor 
neurons were cultured and transduced with different LV vectors. Cells were treated 
with PI and fixed 5 days post transduction. Live and dead cells were identified by 
PI positive or PI negative staining respectively. a) Cells were not treated with H2O2. 
b) Cells were treated with H2O2 five days post transduction. Statistical analysis was 
performed using one-way ANOVA test (Mean ± SEM). n=3. *; p < 0.05, **; p < 
0.01, ***; p <0.001 
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Figure 3.17: Non-transgenic motor neuron survival. Primary motor neurons 
were cultured and transduced with different LV-vectors. Cells were treated with PI 
and fixed 5 days post transduction. Live and dead cells were identified by PI 
positive or PI negative staining respectively. a) Cells were not treated with H2O2. 
b) Cells were treated with H2O2 five days post transduction. Statistical analysis was 
performed using one-way ANOVA test (Mean ± SEM). n=3. *; p < 0.05, **; p < 
0.01 
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 4.4 Discussion  
LV vectors are suitable gene transfer vectors for in vitro experiments as they 
mediate long-term sustained gene expression with low toxicity (Blomer et al., 1997). 
This was specifically important for experiments on primary motor neurons as they are 
very sensitive cells and transfection buffers were shown to be causing tremendous cell 
death. Therefore, LV-based vectors were designed and produced at high titres. HC-
ARFIP2 was the main gene of interest as our hypothesis was that HC-ARFIP2 could 
promote motor neuron survival. LV-based vectors expressing FL-ARFIP2 and TDP43 
were produced to be used as controls. 
Though LV subcloning and production is a preparatory step, it was crucial in order 
to achieve the aim of this chapter. The procedure for producing a virus expressing our 
gene of interest was time consuming and involved many steps, in which the gene of 
interest was cloned by PCR to add the restriction sites required for the subcloning. The 
LV-backbone was digested using enzymes corresponding to the restriction sites 
expressed on the PCR products. Then the PCR products and the LV-backbone were 
ligated to produce the LV-plasmid. The plasmid was validated by sequencing and 
transfection for efficiency. After that, it was used for viral production using the 4 
plasmids transfection method. The viral product was titered by p24 ELISA kit and 
validated by transduction and western blotting. The results showed that efficient 
viruses have been produced with high titres suitable for in vitro studies.   
The HA-tag facilitated the evaluation of protein expression in western blot and the 
identification of cells overexpressing our genes of interest in immunostaining. 
Measuring the overexpression level of FL-ARFIP2 and HC-ARFIP2 is not required, 
as they were detected through a specific tag.  
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The aim to achieve efficient gene transfer with minimal neuronal toxicity was 
achieved by using LV-based vectors as shown in figure 3.14. It also revealed that good 
expression efficiency was accomplished, as substantial number of cells were HA 
positive. 
Though immunostaining of cells using anti-HA-tag antibody was successful, the 
fluorescence intensity was quite low and bleached quickly. This made it hard to 
capture good high-resolution pictures using the confocal microscope. Counting the 
cells using fluorescent microscope, led to some level of bleaching of the fluorescence 
signal. This also made it challenging to obtain high-resolution images. 
Propidium iodide (PI) exclusion assay was performed to investigate the effect of 
Arfaptin2 or HC-ARFIP2 expression on cell viability. PI binds to nucleic acids (DNA 
and RNA) by intercalating between bases. It is membrane-impermeable; therefore, it 
is excluded from viable cells. PI gives red fluorescence upon excitation. PI was used 
in combination with Hoechst 33342 dye, which is a nucleic acid stain that binds to 
double stranded DNA and emits blue fluorescence upon excitation. In contrast to PI, 
Hoechst is membrane permeable. Therefore, Hoechst is used to identify viable cells 
while the PI is used to identify apoptotic cells. This method was used due to its 
simplicity and economical use. 
 Results presented in figures 3.16 and 3.17 supported the hypothesis that 
expression of HC-ARFIP2 significantly increase cell survival compared to other 
treatments and controls even in the presence of oxidative stress. This allows us to 
conclude that HC-ARFIP2 expression increases motor neuron survival regardless of 
oxidative stress and SOD1 mutation. This also corroborates with the findings 
generated by a previous MSc student in our team (Kong, 2011) which demonstrated 
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that HC-ARFIP2 expression enhances survival of NSC34 cell line regardless of H2O2 
or SOD1G93A expression.  
H2O2 treatment was used to investigate whether HC-ARFIP2 can protect against 
oxidative stress. Previous detailed investigation of H2O2-induced primary neuron 
survival showed that short; as little as 30 min, exposure to H2O2 is enough to induce 
significant cell death in a dose-dependent manner. The effective dose was from 100 
µM (Whittemore et al., 1995, Fan et al., 2012, Konyalioglu et al., 2013). Therefore, 
we used a high concentration of H2O2 with a short exposure for 50 min to induce 
oxidative stress. However, comparison of figures 3.16a and 3.17a with 3.16b and 
3.17b shows that there is roughly 10% cell death induced in H2O2 treated cells, which 
was much lower than expected. This could be due to two reasons. Firstly, it could due 
to the short time delay between the treatment and the fixation in which cells were fixed 
~20 min after H2O2 treatment. Many experimental procedures incubate the cell-lines 
in medium for around 24 hours after the treatment, which allows the cytotoxic effect 
to be more obvious and detectable (Abdo et al., 2010, Park et al., 2015, Zhu et al., 
2015). However, it should be noted that primary neurons are more sensitive than 
neuronal cell lines (Fan et al., 2012); therefore, we preferred the short time delay. 
Secondly, this low cell death could be due to low H2O2 potency. It was shown 
previously that a delay of more than 5 min between the preparation and the application 
of H2O2 reduces its efficacy and cytotoxic effect (Whittemore et al., 1995). In this 
project, a diluted H2O2 solution was prepared at least one hour before the treatment, 
which could have affected its efficiency.  
In figure 3.17, although the difference in survival between HC-ARFIP2 
expressing motor neurons and control was not significant, it was significant in all other 
experiments, and there was a noticeable trend of increased survival of NTG motor 
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neurons overexpressing HC-ARFIP2. The lack of significant difference might be due 
to high variability between samples, technical issues or insufficient number of repeats. 
TDP43 overexpression was used as a positive control for cell death and was 
expected to decrease cell survival compared to control as it has been shown that 
TDP43 overxpression is toxic to cells (Ash et al., 2010). However, a significant 
decrease in cell survival transduced with LV-TDP43 was only observed with TG 
motor neurons. The insignificant difference in other experiments might be due to the 
fact that TDP43 induced cytotoxicity is dose dependent (Wu et al., 2013). Therefore, 
an optimisation of TDP43 expression level and cytotoxic effect could have altered the 
outcome of the experiment. 
Our data served as a proof of concept that HC-ARFIP2 expression can increase 
motor neuron survival in vitro. These results achieved the aims of this chapter and 
provided confidence to move forward to investigate the downstream effectors by 
which HC-ARFIP2 exerts its pro-survival effect. 
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4.1 Introduction 
A previous study showed that ARFIP2 is involved in Huntingtin protein 
aggregation through the Akt pathway (Rangone et al., 2005). In addition, Akt is a 
known downstream effector of Rac1 (Stankiewicz and Linseman, 2014). Akt, also 
known as protein kinase B (PKB), has many downstream effectors that exert different 
functions. It is a pro-survival kinase involved in many cellular processes including cell 
survival, protein synthesis and degradation, and RNA transcription (Figure 4.1). Akt1, 
Akt2 and Akt3 genes produce three closely related kinases, Akt1, Akt2 and Akt3, 
respectively. Akt1 and 2 are ubiquitously expressed in different types of cells while 
Akt3 is predominantly expressed in the brain.  
The involvement of Akt pathway in ALS has been implicated in several studies 
(Wagey et al., 1998, Yin et al., 2012, Peviani et al., 2014). Phosphorylated Akt 
(Phospho-Akt), which is the active form, was found to be drastically decreased in ALS 
patients’ post mortem spinal cord, despite their variable disease backgrounds (Dewil 
et al 2007). In addition, Akt expression was found to be downregulated in muscles of 
ALS patients compared to normal and spinal muscular atrophy (SMA) individuals and 
therefore it has been suggested to use Akt as a biomarker for ALS (Yin et al., 2012). 
This downregulation of phospho-Akt seems to occur early in the disease process, as 
phospho-Akt was downregulated in large motor neurons of pre-symptomatic 
SOD1G93A mouse model as well (Dewil et al., 2007). Taken together, these 
observations indicate the importance of this pathway in the pathogenesis of ALS in 
general, regardless of the genetic background. In addition, its involvement in ALS 
seems to be in both motor neurons and muscles, which are among the affected cells 
and tissues in ALS. Therefore, the Akt pathway seemed an interesting and logical 
target to investigate the downstream effectors of HC-ARFIP2.  
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4.2 Aim  
The aim of this chapter is to understand the pathway by which HC-ARFIP2 exerts 
its neuroprotective effect by looking at downstream effectors. In this Chapter, we 
focused on proteins in the Akt pathway (Figure 4.1).  
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Figure 4.1: Schematic presentation of Akt/mTOR pathway and their role in 
protein degradation. After stimulation, Phosphoinositol 3 kinase phosphorylates 
phosphoinositol bisphosphate (PIP2) into phosphoinositol trisphosphate (PIP3). 
PIP3 induces phosphoinositide-dependent kinase-1 (PDK1) which then 
phosphorylates Akt at Ser473 and Thr308. Activated Akt can induce cell survival 
by direct effect on Bcl2 pro-survival proteins family or by inhibition of Bcl2 pro-
apoptotic and the forkhead pro-apoptotic proteins families. In addition, phospho-
Akt activates the mTORC1 pathway, which induces protein synthesis and inhibits 
protein degradation by inhibiting autophagy. On the other hand, Akt can induce 
protein degradation in an mTORC1 independent manner in which inhibition of 
FoxO3 induces protein degradation. LC3II binds to the inner and outer layer of the 
phagophore for elongation of the autophagic membrane and recruits p62. p62 
carries the ubiquitinated unfolded protein to the phagophore. Proteins then are 
degraded in the autophagosome after fusing with lysosomes. 
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4.3 Results 
4.3.1 HC-ARFIP2 increases phospho-Akt 
HEK293T cells were transduced with LV-HC at MOI40 or MOI80 to study its 
downstream effectors. In addition, cells were transduced with LV-GFP and LV-
ARFIP2 as controls beside the untransduced control. As Figure 3.9 showed efficient 
expression of FL-ARFIP2 in HEK293 cells using MOI30 and as we observed 
constantly that LV-ARFIP2 leads to more expression compared to LV-HC, MOI40 
was used for LV-ARFIP2. Tests using LV-GFP within our group showed that MOI10 
is highly efficient and therefore MOI10 was used for this virus throughout. Cell lysates 
were collected 5 days post-transduction and western blot analysis was performed to 
detect different proteins within the Akt pathway. First, the total Akt and the phospho-
Akt expression levels were investigated using anti-Akt and anti-phospho-Akt at 
Ser473, respectively. Band densities were determined using densitometry. Readings 
from 3 independent experimental repeats were obtained.  
After normalisation against GAPDH, Figure 4.2a and b show that LV-HC 
transduction induced phospho-Akt expression significantly compared to the 
untransduced control and the LV-GFP and LV-ARFIP2 controls. Phospho-Akt levels 
were increased to approximately 2.5 fold with both MOIs (n=3; p<0.01). On the other 
hand, LV transduction did not seem to have effect on the overall Akt expression level 
(Figure 4.2c and d). 
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Figure 4.2: LV-HC transduction effect on Akt and phospho-Akt. a) Western blot 
membrane showing phospho-Akt detected using Ser473 phosphorylation specific 
antibody. b) The phospho-Akt expression level was compared between samples after 
normalisation with GAPDH. c) Western blot membrane showing the total Akt 
detected using anti-Akt antibody. d) The Akt expression level was determined as 
above. Statistical analysis was done using One-way ANOVA test (Mean ± SEM). 
n=3. * p <0.05. ** p <0.01. ***p <0.001 
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4.3.2 HC-ARFIP2 induces p62 expression 
Downstream of phospho-Akt we looked at the expression of p62, which is involved in 
both protein degradation pathways; UPS and autophagy. The same lysates described 
in section 4.3.1 were used to evaluate changes in p62. Results in figure 4.3 reveal that, 
although not significant, there is a noticeable increase in p62 expression in cells 
transduced with LV-HC at both MOIs compared to UTD controls. However, 
interestingly LV-GFP transduced cell lysates also show increased p62 expression, 
which could question the reliability of GFP as a control, for which LV-ARFIP2 served 
as an extra control. 
 
 
 
 
Figure 4.3: LV-HC transduction effect on p62 expression in HEK293T cells. 
Western blot shows the expression of p62 at 62kDa and the GAPDH loading control 
at 36kDa. The protein expression levels were determined by densitometry of the 
bands. The p62 expression level was compared between samples after normalisation 
with GAPDH. Statistical analysis was done using One-way ANOVA test (Mean ± 
SEM). n=3.  
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4.3.3 HC-ARFIP2 increases autophagy markers  
We also looked at three autophagy markers in which LC3II and ULK1 activation 
indicates the activation of autophagy, while phospho-Akt inhibits Atg13, which is an 
inhibitor of autophagy. LC3 is a widely used marker for autophagosome formation. 
There are two forms of LC3, which are LC3I the inactive cytoplasmic form and LC3II 
which is the active lipid bound form and is involved in the elongation of the 
autophagosome membrane (Kabeya et al., 2000). Figure 4.4 shows that LV-HC 
transduction of HEK293T cells induces LC3-II expression significantly, at least at 
MOI80, compared to controls (n=3; p<0.05). HC-ARFIP2 modulation had no 
significant effect on LC3I expression.  
In addition, Figure 4.5a and b shows that HC-ARFIP2 significantly increased 
ULK1 expression at high MOI. However, no significant change in the expression of 
Atg13 was observed (Figure 4.5c and d). 
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Figure 4.4: LV-HC transduction effect on LC3I/II expression in HEK293T 
cells. a) Representative western blot from one repeat showing the two bands of 
LC3I and II at 18 and 16kDa, respectively. b and c show the expression level of 
LC3I and II, respectively, after normalisation to GAPDH expression. Statistical 
analysis was done using One-way ANOVA test (Mean ± SEM). n=3. * p <0.05. ** 
p <0.01. 
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Figure 4.5: LV-HC transduction effect on ULK1 and Atg13 expression in 
HEK293T cells. Western blots are representative from one repeat. a and b) ULK1 
expression level was measured by densitometry and normalised to GAPDH from 3 
repeats and represented in the bar chart. c-d) Atg13 expression on western blot was 
measured by densitometry and normalised to GAPDH. Statistical analysis was 
done using One-way ANOVA test (Mean ± SEM). n=3. * p < 0.05 
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4.3.4 HC-ARFIP2 has no effect on 4E-BP1 phosphorylation 
To investigate the effect of HC expression on mTORC1 pathway, we looked at 
the expression of the phosphorylated 4E-binding protein 1 (p-4EBP1), which is the 
active form and is a downstream target for mTORC1. When phosphorylated, p-4EBP1 
is involved in the stimulation of protein synthesis. The same cell samples described in 
section 4.3.1 were used for p-4EBP1 analysis. p-4EBP1 isoforms are detected as a 
ladder of bands between 15 and 20 kDa (Gingras et al., 1999, Livingstone and 
Bidinosti, 2012). There was no significant difference in p-4EBP1 expression between 
treatments (Figure 4.6). 
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Figure 4.6: LV-HC transduction effect on p-4EBP1 expression in HEK293T 
cells. Representative western blot shows p-4EBP1 detected between 15-20 kDa. p-
4EBP1 expression was normalised to GAPDH expression. The p-4EBP1 
expression level was determined by densitometry of western blot. The p-4EBP1 
expression level was compared between samples after normalisation with GAPDH. 
Statistical analysis was done using One-way ANOVA test (Mean ± SEM). n=3.  
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4.3.5 HC-ARFIP2 decrease PTEN expression 
We wanted to look upstream of Akt to determine whether HC acted via PI3K or 
not. Therefore, we looked at the PTEN protein expression in the same cell lysates 
mentioned in section 4.3.1. Figure 4.7 revealed that the expression of PTEN 
significantly decreased to less than 50% in the presence of LV-HC treatment at MOI80 
compared to control and other treatments (n=3; p<0.01). However, there was no 
change in the expression of PTEN with LV-HC treatment at MOI40.  
Interestingly, PTEN was consistently detected at ~100kDa in all samples of the 
three repeats, although the actual protein size is 54kDa. The fact that no other bands 
were observed using this antibody questions the specificity of this antibody. 
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Figure 4.7: LV-HC transduction effect on PTEN expression in HEK293T cells. 
Representative western blot membrane shows PTEN expression in parallel to 
GAPDH. The PTEN expression level was determined by densitometry and was 
compared between samples after normalisation with GAPDH. Statistical analysis 
was done using One-way ANOVA test (Mean ± SEM). n=3. ** p <0.01. *** p 
<0.001 
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4.3.6 Validation by immunocytochemistry 
In immunocytochemistry, colocalisation is defined as the observation of two or 
more different molecules labelled with different fluorophores overlapping in the same 
physical location in a cell. The colocalisation of the molecules might indicate an 
interaction between those molecules in vivo (Berggard et al., 2007). To investigate the 
effect of HC-ARFIP2 modulation on the distribution of the proteins investigated in 
this Chapter by western blotting, HEK293T cells were plated on 10mm coverslips and 
transduced with LV-HC or LV-ARFIP2 vectors. Cells were fixed 5 days post 
transduction. Figure 4.8 shows HEK293T cells labelled with anti-phospho-Akt (red) 
and anti-HA (green) to compare intensity and localisation of phospho-Akt in the two 
treatment conditions (LV-ARFIP2 and LV-HC). There were no obvious changes in 
phospho-Akt expression or localisation between the treatments. 
Neither FL-ARFIP2 nor HC-ARFIP2 shows significant effect on PTEN 
immunoflourescence intensity and intracellular distribution in HEK293T cells (Figure 
4.9). 
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Figure 4.8: Immunostaining for overexpressed FL-ARFIP2 and HC-ARFIP2 
with phospho-Akt in HEK293T cells. HEK293T cells were transduced with LV-
ARFIP2 or -HC viruses. The overexpressed FL- and HC-ARFIP2 were detected 
using anti-HA antibody (green), while phospho-Akt in (red). Scale bar = 20µm 
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Figure 4.9: PTEN immunostaining in cells overexpressing FL-ARFIP2 or HC-
ARFIP2. HEK293T cells were transduced with LV-ARFIP2 or -HC viruses. The 
overexpressed FL- and HC-ARFIP2 were detected using anti-HA antibody (green) 
while PTEN was detected with anti-PTEN (red). Scale bar = 20µm 
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Similarly, none of the autophagy markers used (LC3 and ULK1) were expressed 
differently between FL-ARFIP2 expressing and HC-ARFIP2 expressing cells based 
on immunoflourescent labelling (Figure 4.10).  
 
 
 
Figure 4.10: FL-ARFIP2 and HC-ARFIP2 has no effect on autophagy 
markers in immunostaining. HEK293T cells were transduced with LV-ARFIP2 
or -HC viruses. The overexpressed FL- and HC-ARFIP2 were detected using anti-
HA antibody (green). a and b shows endogenous LC3 and ULK1, respectively 
(red). Scale bar = 20µm 
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A previous study using plasmid transfection in the NSC34 cell line showed that 
overexpressed Arfaptin2 colocalised with SOD1 in aggregates while HC-ARFIP2 
colocalised with SOD1 distributed throughout the cytoplasm (Kong, 2011). To check 
whether the same observation was seen using LV-transduction, we transduced 
HEK293T cells with LV-ARFIP2 or LV-HC and immunolabled them with anti-SOD1 
and anti-HA antibodies. Notably, both FL-ARFIP2 and HC-ARFIP2 colocalise with 
endogenous SOD1 in HEK293T cells (Figure 4.11). In addition, FL-ARFIP2 
colocalised with SOD1 in aggregates in cells overexpressing FL-ARFIP2. On the other 
hand, HC-ARFIP2 colocalised with SOD1 in a diffuse manner in the cytoplasm of 
cells expressing HC-ARFIP2, which was expected based on findings reported 
previously in our group using the NSC34 cell line (Kong, 2011).  
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Figure 4.11: HA-tagged ARFIP2 colocalises with SOD1. HEK293T cells were 
transduced with LV-ARFIP2 or -HC viruses. The overexpressed FL- and HC-
ARFIP2 were detected using anti-HA antibody (green). Endogenous SOD1 was 
detected by anti-SOD1 antibody (red). Scale bar = 20µm 
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4.4 Discussion  
Accumulating evidence shows that activation of Akt pathway could induce motor 
neuron survival in vitro and in vivo (Dewil et al., 2007, Takata et al., 2013, Tsai et al., 
2013, Peviani et al., 2014). Phospho-Akt loss has been also described in Alzheimer’s 
disease (AD) and PD in addition to ALS, which stresses its importance for neuronal 
survival. 
Our results show that HC-ARFIP2 works on the Akt pathway by decreasing active 
PTEN and hence increases Akt activation. Although PTEN was consistently detected 
at ~100 kDa on western blots, PTEN dimerization is normal and it has been reported 
that homo-dimerization does not affect the activity of PTEN. In fact, dimeric PTEN 
showed increased activity compared to monomeric PTEN (Papa et al., 2014). The 
inability to detect PTEN monomer might be due to inefficient denaturation. However, 
there was no other band detected in the background, which supports the antibody 
specificity. 
HC-ARFIP2 increases Akt activation without effecting its expression. This 
finding is supported by the outcome of a previous study showing that decreased 
phospho-Akt expression was not linked to changes in Akt expression, as Akt 
expression was the same in SOD1G93A and control mice. This indicates that a defect 
in the activation of Akt occurs rather than loss of Akt expression (Dewil et al., 2007). 
These results are promising as they support a previous study, which showed that 
increased activation of Akt3 in vitro and in vivo increases neuronal survival (Dewil et 
al., 2007). In addition, motor neurons had increased survival in response to 7,8-
Dihydroxyflavone through activation of the Akt pathway (Tsai et al., 2013). 
Interestingly, the Alsin protein, which is linked to FALS, consists of a GEF domain, 
which activates Rac1. It has been shown that overexpression of Alsin protein has a 
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neurprotective effect that is Rac1-dependent and PI3K/Akt-mediated (Kanekura et al., 
2005).  
p62 protein is involved in UPS and autophagy protein degradation pathways. It 
binds to ubiquitinated proteins and carries the misfolded protein to the proteasome 
subunit for degradation. In addition, p62 drives the misfolded protein to the 
autophagosome by binding to the LC3II units that are bound to the inner side of the 
phagophore during the autophagosome membrane elongation. As p62 is correlated 
with protein degradation, we sought to check its expression after HC-ARFIP2 
modulation. No statistically significant difference was observed in the expression of 
p62 when HC-ARFIP2 is expressed. This statistical insignificance could be due to low 
number of experimental repeats. 
Autophagy and UPS are cooperating mechanisms in which one can compensate 
for any defect in the other one. Therefore, it was interesting to look at the effect of 
HC-ARFIP2 expression on autophagy markers. HC-ARFIP2 seems to increase 
autophagy markers as well, at least with high MOI. This might indicate that HC-
ARFIP2 works in an mTOR-independent pathway. To confirm our hypothesis, we 
looked at mTORC1 pathway downstream effectors. Two of the known downstream 
effectors of mTORC1 are P70S6K and 4E-BP1. With p70S6K we could not detect any 
expression. Regarding 4E-BP1, there was no change in protein expression. This 
suggests that HC-ARFIP2 promotes protein degradation without affecting protein 
synthesis. Future validation of the involvement of mTORC1 pathway in HC-ARFIP2 
effect could be studied using known mTORC1 inhibitors. 
Our results revealed that markers of autophagy (ULK1 and LC3II) were 
upregulated in response to HC-ARFIP2 expression, at least at MOI80. These indicate 
that HC-ARFIP2 might exert its neuroprotective effect by inducing protein 
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degradation, at least partially, by autophagy. Indeed, a previous study suggested 
autophagy activation as a therapeutic target for neurodegenerative diseases (Wang et 
al., 2012). It was demonstrated that activation of autophagy by inhibiting mTOR using 
rapamycin (mTOR-dependent pathway) or autophagy activation in an mTOR-
independent pathway using spermidine or carbamazepine, both rescued MND 
phenotype and enhanced cognitive performance of FTLD mouse model with TDP43 
proteinopathy. This rescue was accompanied by increased LC3II expression and 
decreased protein aggregation (Wang et al., 2012). These findings are further 
supported by a recent study on primary neurons and human stem cell-derived neurons 
and astrocytes carrying TDP43 mutation (Barmada et al., 2014).  
Increased PI3K expression and activity in post mortem spinal cord of ALS patients 
was reported, while no change in Akt and mTOR (P70s6k) activity might indicate a 
disrupted pathway that could lead to neuronal death (Wagey et al., 1998) 
The effect of Akt signalling pathway on autophagy and its role in 
neurodegeneration or survival is still controversial. Activation of PI3K/Akt pathway 
is important for cell survival. However, inhibition of autophagy by mTORC1, which 
is a downstream effector of Akt activation, might compromise cell viability and cause 
cell death. On the other hand, in response to stress, autophagy has been reported to 
induce autophagic-programmed cell death (Shimizu et al., 2004). Several studies 
showed that autophagic machinery is disrupted in neurodegenerative diseases. 
Therefore, the balance between activation of Akt and autophagy is vital and it is crucial 
to understand the mechanism behind it.  
Although LC3II expression is used as a marker of autophagy, whether it means 
there is increased protein degradation by autophagy or there is an increased 
autophagosome formation without increasing protein degradation needs to be 
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elucidated by measuring the protein turnover or autophagic flux using known 
autophagy activator or inhibitor. Thus, we are cautious about interpreting the results 
as they stand.  
In addition, it would be interesting to investigate HC-ARFIP2 effects on the 
expression of anti-apoptotic proteins downstream of Akt, such as Bcl-2, Bcl-xl and 
XIAP. This could elucidate whether HC-ARFIP2 works strictly on protein degradation 
or has multiple downstream targets. However, due to time restriction during the 
current PhD project, the expression of these proteins was not investigated. 
Furthermore, it would be interesting, and probably more accurate, to investigate 
the effect of HC-ARFIP2 expression in neuronal cell lines, primary motor neurons and 
mixed primary cultures and observe if there is a differential effect between cell types.  
To conclude, the prosurvival effect of LV-HC seems to occur through the 
PI3K/Akt pathway and may involve activation of autophagy. Although HEK293T 
cells are not the best model for MND investigation, the above results are encouraging 
and support, at least partially, our hypothesis.  
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5.1 Introduction 
Gene therapy is the treatment of a disease by introducing a nucleic acid to the cells 
to modulate the defective gene, which is replaced, deleted, upregulated or repaired. 
There has been a huge improvement in the field of gene therapy. However, gene 
therapy for CNS diseases presents more challenges due to its complexity and the 
presence of the blood brain barrier (BBB), which is a highly selective permeable 
barrier that protects the CNS from changes in the blood, infections and toxins and 
hence maintain the homeostasis of the CNS. Substances such as water, gases and lipid-
soluble molecules cross the BBB by passive diffusion. Other nutrients enter the CNS 
through active transport via receptors on the endothelial cells. Although the BBB 
protects against infiltration of microbes to the CNS, some bacteria release cytotoxins 
that effect the tight junctions and allow the infiltration of these microbes to the CNS 
(Turowski and Kenny, 2015). Hence, the BBB stands in the way of treatments to reach 
the target cells of the CNS. Therefore, to be an efficient therapy, vector-mediated gene 
transfer has to reach the CNS effectively, have long-term expression, very low toxicity 
and high specificity to the target cells. In addition, gene therapy for ALS has to be 
effective even when introduced after the onset of clinical symptoms, as it is usually 
undiagnosed until clear symptoms have appeared.  
Adeno-associated virus (AAV) is from the Parvoviridae family. It consists of a 
single-stranded DNA genome, which requires a helper virus or a cellular stress to 
promote the production of the complementary strand and replication. This causes slow 
onset of expression. In order to eliminate this step, a self- complementary adeno-
associated virus (scAAV) was generated, in which the two ends of the single-stranded 
DNA complement each other and produce an intra-molecular double strand upon 
release from the viral particle (McCarty et al., 2001, McCarty et al., 2003). scAAV 
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showed significantly quicker and much higher transduction efficiency compared to 
conventional single-stranded AAV (McCarty et al., 2001, McCarty et al., 2003, Wang 
et al., 2003, Duque et al., 2009, Gray et al., 2011, Aschauer et al., 2013). 
CNS exposed to AAV vectors showed no or low immune response and no toxicity, 
which indicates the likely safety of AAV vectors for long-term treatment. 
Furthermore, AAV vectors showed the ability to transduce quiescent cells, which is 
beneficial for motor neuron transduction (Duque et al., 2009, Aschauer et al., 2013).  
AAV can infect a broad range of cells of the CNS, and AAV serotype 9 (AAV9) 
showed generally higher transduction efficiency compared to other serotypes 
(Aschauer et al., 2013). However, different AAV serotypes have different cellular 
tropism, for example, AAV9 transduced cortical neurons with higher efficiency 
compared to other serotypes, while AAV5 had higher transduction efficiency in the 
striatum, especially for astrocytes (Aschauer et al., 2013). 
Mounting evidence suggests that scAAV9 is able to transduce cells of the CNS 
with high efficiency, safety and long-term expression (Kaspar et al., 2003, Duque et 
al., 2009, Foust et al., 2009, Foust et al., 2010, Valori et al., 2010, Gray et al., 2011, 
Aschauer et al., 2013, Benkhelifa-Ziyyat et al., 2013, Yamashita et al., 2013). Another 
advantage for scAAV9 is that it can be introduced to the CNS using non-invasive 
techniques, which is ideal for patients to improve their quality of life. scAAV9 has the 
ability to cross the blood brain barrier as intravenous injection of scAAV9 vector 
expressing the survival motor neuron (SMN) gene was able to transduce motor neurons 
without the requirement of BBB disrupting agents, upregulate SMN protein 
expression and improve the survival of the SMA mice, cats and nonhuman primate 
models (Duque et al., 2009, Foust et al., 2010, Valori et al., 2010). Furthermore, gene 
silencing in the CNS is achievable using scAAV9 as a vector (Little et al., 2014). The 
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ability to cross the blood brain barrier was demonstrated even in well-developed adult 
animal models (Duque et al., 2009, Foust et al., 2009, Foust et al., 2010). This is an 
important aspect when choosing a gene therapy vector for ALS as it is mostly an adult 
onset disease. However, the exact mechanism of how scAAV gains access through the 
blood brain barrier is still unknown. Although, the highest percentage of transduced 
cells in adult mice were astrocytes (Foust et al., 2009), scAAV9 cannot be ruled out 
as an option of ALS gene therapy as astrocytes have been implicated in the 
pathogenesis of ALS (Haidet-Phillips et al., 2011, Pirooznia et al., 2014).  
In addition, scAAV9 is able to undergo retrograde axonal transport upon 
intramuscular injection. Intramuscular injection of scAAV9-SMN virus demonstrated 
that it was possible to transduce cells of the CNS using this method of virus delivery, 
not just motor neurons which innervated the injected muscle, and significantly 
improve the survival of the SMN mouse model (Benkhelifa-Ziyyat et al., 2013).  
In ALS, at disease onset intramuscular injection of AAV vector carrying 
neurotrophic factors, such as insulin growth factor 1 (IGF-1) or glial cell line-derived 
neurotrophic factor (GDNF), showed the ability to undergo retrograde transfer and 
transduce motor neurons in the lumbar and thoracic spinal cord and hence slowed the 
disease progression and induced survival of SOD1G93A mice (Kaspar et al., 2003). 
However, the effectiveness of those proteins was modest as they extended the life span 
by 22 days with IGF-1 and 7 days with GDNF compared to controls. In addition, the 
controls used were injected with GFP-expressing virus, which is known to be toxic; 
therefore, this effect on life span might be negligible if compared to non-treated 
controls (Kaspar et al., 2003).  
A study targeting another aspect of ALS using AAV9 as a vector and intravenous 
injection as mode of administration, found that controlling the calcium permeability 
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through AMPA receptor increased the motor neuron survival. However, the effect on 
motor neuron survival was just around 15% and the effect on life span was not 
investigated (Yamashita et al., 2013). 
5.2 Aim 
Based on the results in Chapter 4, we aim to investigate the effect of HC-ARFIP2 
expression on an in vivo ALS mouse model. Hence, for the above reasons, we chose 
scAAV9 as a vector to deliver HC-ARFIP2 to the CNS of SOD1G93A mice as those 
advantages could not be accomplished using LV vector (Kaspar et al., 2003). This will 
help to efficiently express the protein of interest in vivo. In addition, our aim is to 
introduce the gene of interest using a non-invasive technique as the scAAV9 showed 
the capability to cross the blood brain barrier and efficiently transduce the cells of the 
CNS. Using this method of virus delivery, the ultimate aim is to improve the quality 
of life of ALS patients.  
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5.3 Results  
5.3.1 Construction of scAAV-ARFIP2, scAAV-HC-ARFIP2 and scAAV-TDP43 
plasmid vectors 
5.3.1.1 Amplification of FL-ARFIP2, HC-ARFIP2 and TDP43 DNA by PCR 
All genes that were used in viral subcloning were amplified by PCR as mentioned 
in section 2.2.3, using different primers. FL-ARFIP2 and HC-ARFIP2 primers were 
designed with AgeI on their 5’end and HA-tag and XbaI on their 3’end. The primers 
for TDP43 contained AgeI restriction site on their 5’end and XbaI on their 3’end. The 
PCR products were run on a 1% agarose gel (Figure 5.1). FL-ARFIP2 is 1kbp, HC-
ARFIP2 is 0.5kbp, TDP43 is 1.25kbp. The desired bands were purified by DNA-gel 
extraction kit. The inserts are ready to be subcloned into scAAV backbone. 
 
 
 
 
 
Figure 5.1: FL-ARFIP2, HC-ARFIP2 and TDP43 PCR products for scAAV 
subcloning. PCR products were run on 1% agarose gel for each gene. The FL-
ARFIP2 DNA is at 1kbp. The HC-ARFIP2 DNA is at ~0.5kbp. The TDP43 DNA 
is at 1.25kbp. 
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5.3.1.2 Digestion of scAAV-backbone 
The scAAV-CMV-GFP plasmid was digested with the same restriction enzymes 
(AgeI and XbaI) to remove the GFP cassette to be replaced with the desired inserts 
(Figure 5.2). scAAV-backbone was gel extracted and purified by gel extraction kit. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: scAAV-CMV-GFP plasmid. scAAV-CMV-GFP plasmid cut by 
AgeI and XbaI. The scAAV-CMV backbone is ~4kbp the GFP size is ~0.7kbp. 
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5.3.1.3 Ligation of scAAV-backbone with the inserts 
The target inserts (FL-ARFIP2, HC-ARFIP2 and TDP43) were ligated into the 
scAAV-backbone using the T4 DNA ligase. XL10-gold cells were transformed with 
the ligation mix. Several colonies were picked and the plasmids were extracted. 
Successful ligations were analysed using AgeI and XbaI restriction enzymes and 
visualised on agarose gel. The expected size for FL-ARFIP2 is 1kbp and the size of 
HC-ARFIP2 is ~0.5kbp. However, the XbaI site appeared to be blocked by 
methylation as AgeI single digestion linearized the plasmid and XbaI did not cut the 
plasmid (Figure 5.3). Therefore, SbfI and PsiI restriction sites were used instead of 
XbaI to validate the insertion of FL-ARFIP2 and HC-ARFIP2 into the backbone of 
scAAV vector. Figure 5.4 shows plasmid maps of scAAV-ARFIP2 and scAAV-HC. 
It also shows successful double digestion of scAAV-ARFIP2 and scAAV-HC using 
AgeI with SbfI which is 11bp before XbaI, or PsiI, which is 89bp before XbaI. 
Therefore, the expected size of FL-ARFIP2 cut by AgeI and SbfI is 1079bp while FL-
ARFIP2 cutted by AgeI and PsiI is 1154bp. The size of HC-ARFIP2 cut by AgeI and 
SbfI is 572bp while AgeI and PsiI cut fragment size 647bp.  
Figure 5.5 shows representative plasmid map of scAAV vector with the TDP43. 
It also shows the successful insertion of the TDP43 to the scAAV backbone as 
validated by digestion showing scAAV-backbone at ~4kbp and TDP43 at 1.25kbp. 
The plasmid was further validated by sequencing. 
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Figure 5.3: scAAV-ARFIP2 and scAAV-HC plasmid validation. scAAV-
ARFIP2 and scAAV-HC plasmids were digested with AgeI and XbaI to detect 
successful ligation. AgeI single digestion shows linearized plasmid while XbaI did 
not linearize the plasmid. Therefore, double digestion of the plasmids in lanes 5-11 
did not show expected bands of scAAV backbone (~4 kbp), ARFIP2 (1 kbp) and 
HC-ARFIP2 (0.5kbp). 
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Figure 5.5: Validation of scAAV-TDP43 successful ligation. a) Plasmid map 
represents the scAAV-TDP43 sequence with unique restriction sites. b) TDP-43 was 
ligated to the scAAV backbone and transformed into XL10-gold cells. Plasmid 
extracts from several colonies were digested with AgeI and XbaI. All samples show 
successful digestion at the right sites (scAAV backbone at 4kbp and TDP-43 at 
~1.25kbp) 
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5.3.2 scAAV-based vectors efficiency testing and purification 
5.3.2.1 scAAV-based plasmids efficiently overexpress the proteins of interest 
HEK293T cells were transfected with scAAV-ARFIP2, scAAV-HC or scAAV-
TDP43 plasmids in order to confirm the efficiency of the plasmids prior to virus 
production. After 3 days of transfection, the proteins were harvested and 
concentrations were determined by BCA protein assay. Western blot was performed 
to determine the expression of FL-ARFIP2, HC-ARFIP2 and TDP43. The FL-ARFIP2 
and HC-ARFIP2 were detected using mouse anti-HA antibody as a primary antibody. 
The successful expression of FL-ARFIP2 or HC-ARFIP2 was evaluated by the 
presence of bands at 38kDa and 19kDa, respectively, in the transfected samples 
compared to the untransfected controls. Figure 5.6 shows successful expression of FL-
ARFIP2 and HC-ARFIP2 as they were detected by anti-HAtag antibody. 
 The TDP43 was detected using rabbit anti-TDP43 antibody as a primary antibody 
and then stained with HRP-conjugated goat anti-rabbit antibody as a secondary 
antibody. The successful overexpression of TDP43 was evaluated by comparison of 
band densities between the transfected and untransfected cells. The densities of the 
bands were determined using Gene tools software from Syngene. Comparing the band 
densities of the scAAV-TDP43 transfected samples with the untransfected control, the 
result shows successful overexpression of TDP43 by over 70 fold (see Figure 5.7).  
Following successful validation of the vector genomes, we then started virus 
production and purification of scAAV-HC. 
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Figure 5.6: Validation of the scAAV-based plasmids expressing FL-ARFIP2 or 
HC-ARFIP2. HEK293T cells were transfected with the scAAV-based plasmids 
expressing FL-ARFIP2 or HC-ARFIP2 using the PEI transfection method. FL-
ARFIP2 and HC-ARFIP2 expression was detected on a western blot by mouse anti-
HA antibody. FL-ARFIP2 is detected at ~38kDa while the HC-ARFIP2 is detected 
around 20kDa. α-tubulin was used as loading control. 
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Figure 5.7: Validation of the scAAV-based vector genome expressing TDP43. 
HEK293T cells were transfected with the scAAV-TDP43 plasmid using the PEI 
transfection method. TDP43 overexpression was detected on a western blot by 
rabbit anti-TDP43 antibody. TDP43 is detected at 43kDa. α-tubulin was used as 
loading control. Densitometry shows over 70 fold increase in the expression of 
TDP43 compared to the untransfected (UTF) sample. 
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5.3.2.2 scAAV-HC virus production and purification 
Once plasmid was validated, scAAV-HC virus was produced by transfecting 
HEK293T cells with the scAAV-HC vector genome and packaging plasmids (pAAV-
2/9 and pHelper) using the PEI transfection method. After 5 days, the media was 
collected and purified as described in Section 2.2.6.2.5. Aliquots of the 40% fraction 
containing purified virus were collected. A sample of each aliquot was run on SDS-
PAGE for purity analysis. SDS-PAGE gels were stained using SYPRO-Ruby protein 
gel stain. Figure 5.8 shows fractions of purified scAAV-HC virus showing the three 
bands representing the virus capsid proteins VP1, VP2 and VP3. Clean high-quality 
(HQ) fractions that showed no other bands were pooled, re-concentrated and desalted. 
HQ prep was re-run on SDS-PAGE to validate the purity (Figure 5.9) 
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Figure 5.8: scAAV-HC fractions analysis. Samples were run on SDS-PAGE and 
stained using SYPRO-Ruby protein gel. Sample numbers 3-9 showing three capsid 
bands were pooled as high quality prep.  
 
 
Figure 5.9: scAAV-HC high quality fraction analysis. HQ prep shows only 3 
bands representing viral capsid proteins VP1, VP2 and VP3.  
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5.3.2.3 scAAV-HC efficiently overexpress HC-ARFIP2 in HEK293T cells 
After production, concentration and purification of scAAV-HC, the viral titre was 
determined by qPCR using two different sets of primers for confirmation as described 
in Section 2.2.6.2.8. Viral titres ranged between 107-1010 viral genomes (vg/ml). To 
validate the efficiency of the produced virus, HEK293T cells were transduced with 
50µl or 100µl of scAAV-HC of which the titre was 2.55*1010vg/ml. Cells were 
harvested 5 days post transduction and the protein was extracted and detected as 
above. 
Figure 5.10 shows that the produced viruses were able to overexpress HC-
ARFIP2. However, the achieved titres above are very low for in vivo applications. Our 
group and others have shown that titres around 1013vg/ml are necessary to be able to 
administer doses ranging from 1x1011-5x1011 vg in mice to achieve high level of gene 
transfer to CNS. After two runs, we could not generate scAAV-HC virus appropriate 
for use in vivo. 
 
 
 
 
 
 
 
 
Figure 5.10: Validation of the scAAV-HC virus. HEK293T cells were transduced 
with 50µl or 100µl of scAAV-HC of which the titre was 2.55*1010vg/ml. HC-
ARFIP2 expression was detected by mouse anti-HA antibody.  
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5.4 Discussion  
The aim in this Chapter was to produce a vector that efficiently overexpresses HC-
ARFIP2 in the CNS of an ALS-mouse model and use it to investigate the effect of 
HC-ARFIP2 expression on SOD1G93A mice survival. Therefore, it was necessary to 
produce high titre scAAV9-based vector that expressed HC-ARFIP2. The plan was to 
use this vector and run an efficacy pilot study in which virus would be administered 
by facial vain injection into WT mice. After 3 weeks, the spinal cord and brain tissues 
would be collected to detect the expression of HC-ARFIP2 using western blot and 
immunohistochemistry. Once expression had been validated, we would proceed with 
a survival study to determine the effect of HC-ARFIP2 expression on the symptoms 
and life span of SOD1G93A mice.  
FL-ARFIP2, HC-ARFIP2 and TDP43 were successfully subcloned into scAAV9 
vectors. As a priority, scAAV-HC production was performed first. scAAV-HC was 
produced successfully and the viral product efficiently transduced HEK293T cells. 
However, the titre of the resulting virus was too low to be used in in vivo experiments. 
The target titres mostly used for in vivo experiments are around 1013-1014vg/ml, which 
could not be accomplished after two attempts for scAAV-HC production, which 
generated virus preps with titres from 107-1010 vg/ml.  
The scAAV production takes approximately 3 weeks from the production of 
plasmid mega prep until the titration of the virus. In addition, as scAAV production 
involves many materials and steps, any of those steps can be the reason of the reduced 
titre. It can be due to technical issues like HEK293T cell viability, plasmid purity, 
plasmid ratios or transfection efficiency. Our team also showed that the transgene 
could influence the titre achieved. Optimising scAAV-HC viral production and 
purification could take several months. Unfortunately, the lack of time as my PhD 
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studentship was ending and based on the outcome of scAAV production and 
purification, we decided not to proceed with the in vivo study.
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6.1 Discussion  
To date and despite the enormous amount of research on ALS, there is no effective 
treatment available for ALS. Finding a treatment for ALS is challenging due to the 
heterogeneity in the underlying pathogenesis of ALS. Although many pathogenic 
mechanisms have been suggested and studied, the primary trigger for the disease 
remains unknown. 
 Although very little is known about the exact function of Arfaptin2, its ability to 
bind to molecules involved in intracellular vesicular transport, indicates the possibility 
of its role in protein inclusion formation. Two independent groups have shown that 
Arfaptin2 is involved in polyQ-huntingtin aggregation in Huntington’s disease (Peters 
et al., 2002, Rangone et al., 2005). To date and to our knowledge, the involvement of 
Arfaptin2 in ALS has not been studied. Accordingly, we sought to explore whether 
Arfaptin2 is involved in protein aggregation in ALS.  
In this project we used primary motor neurons from mouse embryos as a follow 
up on the previous study on NSC34, which are immortalised motor neuron-like cells 
used as models for motor neurons (Kong, 2011). The current study has defined a 
number of important observations and issues that will be discussed in this chapter. 
PI exclusion assay, represented in Chapter 3, was performed to investigate the 
effect of overexpressing FL-ARFIP2 or HC-ARFIP2 on cell viability. At first, 
transfection using Fugene as a transfection reagent was used to express FL-ARFIP2, 
HC-ARFIP2 or TDP43 in primary motor neurons. However, it was observed in some 
experiments that all cells were dead by the end of the incubation period. In some 
experiments where some cells survived, the number was much lower than expected 
and would not be sufficient for statistical analysis and completion of our study. This 
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was true for both transfected and mock transfected controls, which indicated that the 
cytotoxic effect was probably due to the transfection reagent rather than the transfected 
plasmids. In addition, as this reagent was used previously within our group to transfect 
NSC34 cell lines, our observations suggest that primary motor neurons are more 
sensitive to transfection reagents than neuronal cell lines. This also suggests that 
primary motor neurons are better models to investigate motor neuron reaction to 
treatments as they show closer resemblance to normal cells in vivo. On the other hand, 
as far as we know, there is no study investigating the expression level of Arfaptin2 in 
different developmental stages of the CNS. Therefore, it is unknown yet whether 
Arfaptin2 or HC-ARFIP2 expression would have different effects on adult cell lines 
compared to the embryonic cells that we used in this project. Hence, further validation 
of these results on adult cell lines might be required. 
Subsequently, in Chapter 3 subcloning of FL-ARFIP2, HC-ARFIP2 and TDP43 
into LV vector was conducted. LV-based viruses , which mediated expression of FL-
ARFIP2, HC-ARFIP2 or TDP43, were successfully produced. The viral products 
efficiently express the desired proteins in primary motor neurons. Survival assays 
using these vectors showed that HC-ARFIP2 significantly increased motor neuron 
survival by approximately 20% compared to untransduced cells. This protective effect 
was observed clearly when compared to FL-ARFIP2 and TDP43 treated samples, 
where survival was increased by approximately 40% in some cases. This supports 
findings from our previous study (Kong, 2011), where it was shown that HC-ARFIP2 
expression in NSC34 cells increased cell survival compared to controls. The findings 
were similar between WT NSC34 and stably transfected G93A-NSC34 cell lines, in 
both of which survival was increased by 10% when overexpressing HC-ARFIP2.  
Chapter 6: General Discussion 
154 
 
 
As neurodegenerative diseases share some common features, treatments for 
neurodegenerative diseases might be exchangeable; i.e. treatment for one 
neurodegenerative disease might be useful for another neurodegenerative disease as 
well. For example, Neuregulin1 was found to have a neuroprotective effect in AD as 
well as PD models (Carlsson et al., 2011, Ryu et al., 2012, Cui et al., 2013). Similarly, 
we showed in this project that the neuroprotective effect of HC-ARFIP2 that has been 
reported in HD models (Peters et al., 2002) is applicable to ALS in vitro models as 
well. 
It is evident that activation of Akt by phosphorylation has a neuroprotective effect 
(Ning et al., 2004, Kanekura et al., 2005, Dewil et al., 2007, Ning et al., 2010, Takata 
et al., 2013, Tsai et al., 2013, Little et al., 2014, Peviani et al., 2014). Interestingly, 
previous studies showed that administering Fasudil, an inhibitor of the Rho pathway, 
to SOD1G93A mice delayed onset and prolonged survival through upregulation of 
phospho-Akt and downregulation of PTEN (Takata et al., 2013). In addition, Little et 
al. showed recently that knocking down PTEN in an SMA mouse model rescued motor 
neuron function and prolonged life span (Little et al., 2014). These and other 
observations emphasise the importance of this pathway in the development and 
survival of motor neurons. Results in Chapter 4 support those findings, as we showed 
that HC-ARFIP2 expression in HEK293T cells downregulated PTEN, and hence 
upregulated phospho-Akt expression. The enhancement in Akt phosphorylation 
induced the autophagic markers, LC3II and ULK1, suggesting activation of a protein 
degradation pathway. There were no differences observed in activity of 4EBP1, which 
induces protein synthesis and is downstream of the mTORC pathway. Taken together, 
these results indicate that the prosurvival effect of HC-ARFIP2 is through the Akt 
pathway and involves protein degradation. This effect is independent from the 
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mTORC pathway. In this study, we used HEK293T cells, as they are easy to maintain 
and transduce. In addition, they yield  sufficient amounts of protein to be used for 
western blotting.  
The importance of the results presented in this thesis lies in the possibility to apply 
this concept to other proteinopathies. Some neurodegenerative diseases share features 
such as accumulation of misfolded proteins. In addition, Akt dysregulation has been 
implicated in different neurodegenerative diseases. For example, Prion disease is a 
neurodegenerative disease and a proteinopathy that is characterised by the 
accumulation of misfolded prion protein. Research showed that the Akt pathway is 
dysregulated in in vivo and in vitro models of Prion disease (Shott et al., 2014, Simon 
et al., 2014). It was shown that activation of Akt ameliorates toxicity in cells 
expressing mutant prion protein (Simon et al., 2014). One of the histopathological 
characteristics of AD is the accumulation of β-amyloid peptides. A combination of 
microRNA (miRNA) sequencing and miRNA-target prediction methods used to 
compare microRNA expression levels in the brain of an AD mouse model and controls 
showed that the biggest numbers of differentially expressed miRNAs were affecting 
the PI3K/Akt pathway (Luo et al., 2014). In addition, it was shown that activation of 
the PI3K/Akt pathway in in vitro and in vivo AD models using Neuregulin1beta1 
improved neuronal survival by increasing the expression of Bcl-2, which is a 
downstream anti-apoptotic effector to Akt (Ryu et al., 2012, Cui et al., 2013). 
Similarly, reduction in Akt activity was found in PD models (Wang et al., 2013). 
Targeting the Akt pathway using Fasudil, which is a Rho inhibitor, increased neuronal 
survival in a PD in vivo model (Zhao et al., 2015). Collectively, these findings support 
the significance of the Akt pathway in neurodegenerative diseases and support the idea 
that Akt modulation could rescue from neurodegeneration.  
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Impaired autophagy has also been reported in AD, PD and HD (Boland et al., 
2008, Martinez-Vicente et al., 2010, Ciechanover and Kwon, 2015, De Rosa et al., 
2015). Therapeutic strategies involving induction of autophagy in these diseases 
showed that rescuing autophagy leads to rescue of neurodegeneration (Ciechanover 
and Kwon, 2015). Therefore, the application of HC-ARFIP2 expression to other 
neurodegenerative disease models with featuring protein aggregation could rescue Akt 
dysregulation, increase autophagy and subsequently decrease aggregate formation and 
neurotoxicity. 
Different defects within the autophagy pathway have been described in different 
neurodegenerative diseases. For instance, in HD, defective recognition and 
engulfment of mutant polyQ-huntingtin by autophagosomes was observed rather than 
impaired autophagosome-lysosomal degradation (Martinez-Vicente et al., 2010). In 
an AD model it was demonstrated that AD-linked aggregates are caused by impaired 
autophagosome clearance rather than impaired autophagy activation. This indicates 
that activation of autophagy does not necessarily increase protein degradation (Boland 
et al., 2008). As we showed that HC-ARFIP2 increases some autophagy markers, it is 
necessary to investigate the effect of HC-ARFIP2 on autophagosome formation, 
components and clearance as well; i.e autophagy flux. 
Chapter 5 of the current PhD project outlines the procedure followed for scAAV9-
based virus production. One of the down sides of using viruses as a method of gene 
transfer is the laborious work that needs to be done to obtain these viruses. Though the 
virus design, subcloning and production are preparatory steps rather than “real” 
experiments, they were time consuming and necessary to achieve the aims of the study. 
Finally, an efficient virus was successfully produced, however the viral yield was 
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lower than desired for usage in mouse model studies. Therefore, high titre viral stocks 
will need to be produced for subsequent studies.  
6.2 Conclusion 
In conclusion, the results partially support the theory of involvement of Arfaptin2 
in protein degradation pathways. In addition, HC-ARFIP2 can promote motor neuron 
survival through Akt pathway activation, which indicates that modulation of Arfaptin2 
can be a target for therapeutic strategies for ALS. 
One of the disadvantages of using viruses as a DNA transfer vector is that a “one 
size fits all” concept cannot be applied. As observed in Chapter 3, different constructs 
led to different expression levels using the same MOI. Therefore, a standardised MOI 
cannot be used for all viruses. A more detailed optimisation of the MOI used of each 
virus for each type of cell line might give a more accurate conclusion. 
6.3 Future perspectives 
Firstly, as a subsequent step to this study, the effect of HC-ARFIP2 expression 
needs to be studied in vivo. This could be done using systemic or cerebrospinal fluid 
(CSF) delivery of scAAV9-based vectors. Plasmids produced in this study can be used 
for subsequent future studies as well. In addition, due to the emerging evidence 
showing the role of glial cells in the pathogenesis of ALS, a co-culture study could be 
conducted to determine the effect of Arfaptin2 modulation on motor neuron survival. 
This could determine whether the neuroprotective effect of HC-ARFIP2 is cell type-
dependent.  
Secondly, although primary motor neurons are hard to extract and the protein 
lysate yield is low, it is still necessary toconfirm the downstream effectors of HC-
ARFIP2 in primary motor neurons. In addition, as HC-ARFIP2 showed induction of 
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autophagic markers, autophagy flux should be studied to determine if protein 
degradation is accomplished. Finally, it would be interesting to investigate the 
interaction between Arfaptin2 and SOD1, TDP43 and p62 using immunoprecipitation. 
Additionally, as the colocalisation study did not lead to firm conclusions, it might be 
worth re-investigating the colocalisation of Arfaptin2 with the aforementioned 
proteins to validate their interaction. Furthermore, it would be interesting to 
investigate the colocalisation of Arfaptin2 with other ALS-linked proteins to 
understand whether Arfaptin2 could be a therapeutic target for a broad spectrum of 
ALS subtypes.  
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Image 2: Permission to reprint publications 
 
 
Appendices 
179 
 
 
Image 3: FL-ARFIP2 sequence (top) alignment with LV-ARFIP2 forward sequencing 
result (middle) and LV-ARFIP2 reverse sequencing result (bottom)  
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Image 4: FL-ARFIP2 sequence (top) alignment with LV-HC forward sequencing 
result (bottom)  
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Image 5: TDP43 sequence (top) alignment with LV-TDP43 forward sequencing result 
(middle) and LV-TDP43 reverse sequencing result (bottom) 
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Image 6: FL-ARFIP2 sequence (top) alignment with scAAV-ARFIP2 forward 
sequencing result (middle) and scAAV-ARFIP2 reverse sequencing result (bottom) 
 
Appendices 
183 
 
 
Image 7: FL-ARFIP2 sequence (top) alignment with scAAV-HC forward sequencing 
result (bottom) 
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Image 8: TDP43 sequence (top) alignment with scAAV-TDP43 forward sequencing 
result (middle) and scAAV-TDP43 reverse sequencing result (bottom) 
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